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ABSTRACT 
 
ERICA S. RINELLA:  Impact of diet on EGFR-targeted treatment of colorectal cancer 
(Under the direction of Dr. David W. Threadgill) 
 
 
 
 
Colorectal cancer (CRC) continues to be one of the most prevalent cancers 
and leading causes of cancer-related deaths in Western societies.  Molecule-
targeted therapies are being developed and tested in preclinical and clinical studies, 
with some promising results.  One such class of therapeutics targets EGFR 
signaling, a pathway often deregulated in epithelial cancers.  While these inhibitors 
have shown some effectiveness in clinical trials, the results have not been as 
promising and consistent as those reported in preclinical trials.  The current study 
addresses these inconsistencies, expanding preclinical investigation to include 
multiple mouse models, genetic strains, and diet in an effort to better predict human 
response to these therapies.  Two mouse models for CRC, ApcMin/+ and AOM, are 
used on distinct inbred strains as well as a shared F1 strain and are maintained on 
either a standard mouse chow (STD) or Western-style diet (WD).  The efficacy of 
small molecule EGFR inhibitor AG1478 varies with respect to model, strain and diet.  
Additionally, human dietary supplementation is addressed, assessing the effect of 
supplementing a Western-style diet with high levels of calcium on AG1478 treatment 
of CRC.  The two mouse models mentioned as well as an in vitro system including 
 iii
two human CRC cell lines, Caco-2 and HCT116, were used to evaluate the impact 
of low (0.05%) versus high (5%) calcium in vivo and increasing calcium 
concentrations in vitro (0.424 – 5.5mM) on AG1478-mediated tumor reduction.  
Calcium consistently impacts AG1478 with an additive effect on tumor growth 
reduction across each model system, however, with potentially toxic side effects in 
vivo.  In addition, gender influences are revealed in response to diet and AG1478 
inhibition of EGFR activity.  We conclude that the diet consumed during cancer 
treatment, including the use of dietary supplements, may impact response to 
conventional therapies, and that understanding gene-environment-therapy 
interactions will be critical in developing and testing new therapies for CRC.   
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ABSTRACT 
   Genetic differences among individuals contribute to differential susceptibility 
to cancer and, undoubtedly, to variable efficacy and toxicity of pharmacological-
based therapeutics.  Many of the specific molecular processes involved in human 
tumorigenesis have been elucidated and accurately modeled in mice. However, the 
current models used for drug testing do not accurately predict how new treatments 
will fare in clinical trials.  More sophisticated models that treat cancer as a complex 
disease present within heterogeneous patient populations will provide better 
predictive power to identify patients who may benefit from specific therapies or who 
may develop potential drug-induced toxicities.  
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INTRODUCTION 
 It is increasingly clear that pharmaceutical-based cancer therapies provide 
variable and often unpredictable patterns of efficacy among patients.  Additionally, 
unpredicted or off-target toxicities within patient populations are a growing concern 
that has been highlighted in the lay press over the last several years.  While animal 
models, especially mice, have been used extensively by the pharmaceutical industry 
for mechanistic studies and safety testing, the commonly used approaches and 
mouse models are not appropriate to address many of the complex genetic and 
environmental contributions underlying varying therapeutic effects and/or toxicities in 
patient populations. Herein we compare current models and suggest new 
approaches to more accurately model heterogeneous patient populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 5
IN VITRO MODEL SYSTEMS 
Cell-Based Platforms 
 Cell-based screens are an efficient and cost effective platform to identify 
potential therapeutic targets, to investigate mechanisms of action, and to assess 
cellular toxicity in early stages of drug discovery.  While these screening approaches 
may be effective in identifying potential therapeutic lead compounds, their predictive 
value for the clinic is limited.  Readily available cancer cell lines have been 
maintained in culture for many generations of passage and usually have acquired 
many unknown genetic alterations.  Uncharacterized mutations may affect the 
validity of conclusions and long-term reproducibility.  It is also not uncommon for cell 
lines to be cross contaminated with other cell lines after many years of repeated 
culturing.  The German Cell Bank (DSMZ) has estimated that 29% of all human-
tumor cell line submissions contain cross contamination (Chatterjee 2007).  While 
certain drugs may have positive results in cell line screens many other physiological 
factors may affect the overall performance of lead compounds including the 
surrounding microenvironment of cancers in vivo and the underlying genetic 
heterogeneity of the patient populations that may affect efficacy, metabolism, as well 
as susceptibility to toxicity.  Strategies using panels of cell lines have been 
developed to overcome some of these limitations, such as the National Cancer 
Institute’s panel of 60 cancer cell lines (http://dtp.nci.nih.gov) that have been used to 
test thousands of chemicals.  Another strategy is to combine in vitro cell-based 
platforms with in vivo growth assays like xenograft models.   
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Xenografts: An In Vivo Petri Dish 
 The current gold standard for testing the efficacy of cancer pharmaceutical 
therapeutics in vivo is the xenograft mouse model.  In this model human tumors are 
subcutaneously implanted into immunodeficient mice and drugs are administered 
either locally or systemically.  Following treatment, tumors are assessed for changes 
in size, vasculature, metastasis to distant sites, among other measures.  Although 
xenografts may be efficient in detecting therapy-induced changes to specific cancer 
cell growth characteristics, the predictive power of this model has been modest at 
best. Previous studies have shown that only 3.8% of patients in Phase I cancer drug 
trials show a significant clinical response (Garber 2006).  Most, if not all, drugs that 
failed in humans worked on subcutaneous xenograft tumors in mice.  It is apparent 
that there is a large discrepancy in the relationship between artificially-implanted 
xenograft models and in vivo arising cancers. 
 While these models may be effective for determining whether pharmaceutical 
drugs hit their appropriate targets and cause changes in specific cancer cell 
characteristics, they have significant shortcomings when compared to spontaneously 
occurring tumors in humans.  One of the main issues is the lack of an intact immune 
system in xenograft recipients, which is a well-established component of cancers 
that can have both growth promoting and growth inhibiting properties.  Another issue 
is that these implanted tumors are grown in a subcutaneous environment lacking a 
host stromal compartment that evolved with the cancer.  Differences in the tumor 
microenvironment compared with the normal tissue of origin may have a profound 
impact on growth and survival of cancer cells as this artificial environment has 
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different cellular compositions and vasculature processes.  Orthotopic implantation, 
injecting the human tumors into the corresponding mouse organ tissue, may resolve 
some of these issues but this route of implantation is not practical due to extensive 
procedure time and the inability to accurately mimic the location and growth 
environment of the human tumors from which the cells were derived.  
Both of the immunodeficient mice commonly used for xenografts, severe 
combined immunodeficient mice (SCID) and Nude mice, are usually maintained on a 
single or mixed genetic background which eliminates the ability to detect host 
specific genetic modifiers that may contribute to varying pharmacological and 
toxicological effects in humans.  Finally, xenograft models platforms rarely 
incorporate important environmental factors, such as diet, in assessing the efficacy 
and toxicity of pharmaceuticals.  With the current knowledge on the role of diet in 
cancer, drug-food interactions, and differential effects of diet across mouse strains 
and humans, the human diet, which is substantially different than normal mouse 
chow, likely contributes to reduced predictive power of mouse models as described 
below.  
The simplistic xenograft model system is generally regarded as not being 
predictive for therapeutic efficacy and has led to significant criticisms of the value of 
mouse models for drug discovery and testing (Leaf 2004), despite the fact that 
xenografts are not mouse models of human cancer but are primarily a complex in 
vivo cell culture system. These models may even be responsible for prematurely 
canceling development of candidate drugs that may have efficacy in humans, but 
data is not available for drug leads not pursued based upon failure in xenograft 
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studies. With the vast majority of cancer pharmaceutical companies using these 
models, despite the low success of subsequently developed drugs in human clinical 
trials, it is apparent that more accurate mouse cancer models must be utilized to 
specifically model the complexity of tumorigenesis as it occurs in humans. 
 
IN VIVO MODEL SYSTEMS  
Advanced Molecular Mouse Models of Cancer  
Transgenic, knock-out, and knock-in mouse models with spontaneously 
arising tumors have been developed that demonstrate many of the molecular and 
histopathological changes associated with human cancer progression from initiation 
through metastasis (see the National Cancer Institute’s Mouse Models of Human 
Cancer Consortium (MMHCC) web site: http://emice.nci.nih.gov).  Although these 
models have been used extensively in basic research investigations into the 
mechanisms of tumorigenesis, their use in pharmaceutical preclinical testing has 
been limited.  With the shortcomings of the xenograft models in cancer drug 
development becoming more widely acknowledged, it is appropriate to entertain the 
use of more complex but realistic mouse models of human cancer for preclinical 
testing.  Unlike xenograft models, engineered mouse models retain an intact 
immune system and a host-derived tumor microenvironment that accurately models 
that present in human cancers.  
The first transgenic mouse models of human cancer were generated in the 
1980s when MYC overexpression in the mouse mammary epithelium led to 
development of adenocarcinoma (Stewart, Pattengale et al. 1984) and mutant KRAS 
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expression led to the oncogenic transformation of pancreatic cells (Quaife, Pinkert et 
al. 1987).  These models demonstrated that expression of human oncogenes in the 
mouse could successfully initiate tumor development.  Subsequently it was shown 
that knock-outs of tumor suppressors such as Trp53 or Rb would induce a spectrum 
of tumors including lymphomas, sarcomas and pituitary adenomas (Donehower, 
Harvey et al. 1992; Jacks, Fazeli et al. 1992; Jacks, Remington et al. 1994). 
Unfortunately, the concept of engineering mice to develop cancer and their use for 
preclinical trials was patented. DuPont licensed the patented ‘OncoMouse’ in 1988, 
preventing the production and exchange of these models without a license.  Many 
have argued that the cost and restrictions imposed by these licenses have hindered 
the adoption of more accurate mouse models by the pharmaceutical industry for 
preclinical therapeutic development and delayed development of more intelligently 
tested drugs, which has increased the cost of drug development despite the lower 
cost of the xenograft models compared to more clinically-accurate engineered and 
spontaneously arising mouse cancer models (Marshall 2002; Shorett 2002). 
Since the first generation mouse models of human cancer were developed, 
numerous and ever more accurate models have become available for most cancers 
including brain, breast, colon, lung, and prostate cancers (Table 1).   Models have 
been designed and built to display varying stages of tumorigenesis ranging from 
initiation through metastatic disease making them useful for evaluating therapies 
against particular stages of cancer progression.  Cancer is a disease with multiple 
mutations and epigenetic alterations usually involving activation of oncogenes (Myc, 
Kras, etc.) and loss of tumor suppressor genes (Trp53, Rb, etc.).  While single gene 
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transgenic and knock-out models are sufficient to induce tumorigenic events in the 
mice, more complex models that recapitulate the multiple genetic events occurring in 
human cancers have been developed.  Illustrative of the remarkable similarity 
between the latest generation of mouse models and human cancer is the 
development of a mouse pancreatic cancer model that progresses from initiation to 
invasive, metastatic disease that was engineered by introducing an activated Kras 
gene with pancreas-specific expression along with loss of the tumor suppressor 
Cdkn2a (Aguirre, Bardeesy et al. 2003).  These two mutations occur in almost all 
cases of human pancreatic adenocarcinomas, yet mice expressing Kras display only 
signs of early stage pancreatic tumor growth while mice lacking Cdkn2a have no 
neoplastic lesions in the pancreas. This mouse model should have specific utility in 
preclinical testing for pancreatic cancer drug development since it recapitulates both 
the molecular and histopathological changes observed in human pancreatic cancer. 
Greater use of genetically engineered immunocompetent mice to model the order 
and spectrum of mutations observed in humans can only improve the predictive 
value of mouse models for the discovery of cancer therapeutics and will lead to 
lower drug development costs because of more informed evaluations in realistic 
models before the expense of clinical trials is incurred.  
 
Genetic Modifiers 
 Pharmacology studies have traditionally used mice from inbred or undefined 
genetic backgrounds for drug discovery and toxicity testing.  However, studies based 
solely on results obtained using one inbred strain or model do not support clinically-
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important insights or the full appreciation of the response spectrum likely to be 
encountered in the clinic. This insight can only be achieved by investigating the 
genetic context of efficacy and toxicity.  Different inbred mouse strains have varying 
susceptibility to spontaneous or chemically-induced tumor formation (Nagase, Mao 
et al. 1999; Mao and Balmain 2003), and specific modifier loci have been identified 
in mice that lead to susceptibility to specific cancers (Malkinson, Radcliffe et al. 
2002; Wang, Lemon et al. 2002) and varying toxicological responses (Festing, 
Diamanti et al. 2001).  For example, the Pas1 locus has been identified to 
predispose mice to lung tumor development (Gariboldi, Manenti et al. 1993). 
Depending on genetic background, the activity of the same allele may even switch 
from resistance to susceptibility to cancer (To, Perez-Losada et al. 2006).  
These differences demonstrate the importance of genetic background in 
cancer development and use of this information may allow better understanding of 
how humans differ in their response to pharmaceutical therapies and/or susceptibility 
to drug-induced toxicities.  A ‘one-size-fits all’ mouse model approach will not be 
sufficient to provide the best preclinical predictive power.   
Genetic background can dramatically modify the effect of engineered 
mutations on tumor growth and survival and by extension, on the efficacy and 
toxicity of preclinical therapeutic trials. Patients developing cancers with specific 
genetic mutations often have different survival rates and respond to therapy with 
varying degrees of success, presumably as a result of unidentified genetic modifiers.  
Although requiring substantial changes from the status quo, incorporating knowledge 
of genetic modifiers into preclinical tests will improve extrapolation of results to 
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patients and identification of patient populations best matched to particular 
therapies, leading to more accurate and cost-effective translation to the clinic.  
Humans are not inbred nor genetically homogeneous so it is over-simplistic to 
assume that a single inbred mouse model will be sufficiently representative of the 
genetic heterogeneity present in patient populations. By identifying and 
understanding modifier loci in mice that alter therapeutic response or susceptibility to 
toxicity, polymorphisms in orthologous genetic loci in patients enrolled in clinical 
trials can be considered to increase the probability of successful translation to the 
clinic.  Inevitably, future cancer therapies will be personalized to the patient’s 
spectrum of tumor mutations and their constitutional genetic makeup.    
 
Diet and Nutrition 
 In addition to genetic predisposition, environmental factors such as diet can 
have a major impact on cancer risk and response to therapy.  It is becoming 
increasingly apparent that knowledge about gene-environment interactions will be 
important for improving cancer prevention and treatment.  According to the American 
Cancer Society, an estimated one-third of all cancer deaths in the U.S. are related to 
lifestyle, such as diet and physical activity (ACS, 2007).  The interaction between 
environment and genetic susceptibility and their influence on cancer deaths also 
varies among cancer type; environment has the greatest impact on cervical, lung 
and oesphageal cancers while leukemia and colorectal cancers are more heavily 
influenced by genetic susceptibility in combination with environmental factors 
(Danaei, Vander Hoorn et al. 2005).  The role of diet in particular has been 
  
 13
examined extensively in animal studies and human epidemiological and clinical 
trials.  
 The ‘Western-style’ diet consumed in North America and Europe that has 
high levels of fat and low levels of vitamin D and calcium has been modeled in 
mouse experiments. Maintenance of mice on this diet induces hyperproliferation in 
pancreatic, prostate, mammary and intestinal epithelial cells of wild-type C57BL/6 
mice (Newmark, Lipkin et al. 1990; Xue, Lipkin et al. 1999).  Further modification of 
the diet to include decreased levels of folate and other nutrients essential for DNA 
methylation induces intestinal adenomas and carcinomas in wild-type mice 
(Newmark, Yang et al. 2001).  Combining a Western diet with inactivation of 
Cdkn1b, coding for a key cell cycle regulator, results in an additive effect on 
intestinal tumorigenesis compared to Western diet or Cdkn1b mutations alone 
(Yang, Bancroft et al. 2003).  Despite the dearth of studies in this area, analogous 
effects on therapeutic response or susceptibility to drug-induced toxicity are 
predicted to occur. 
 Another factor not usually considered is the more than fifty percent of adults 
taking at least one type of dietary supplement.  Recent studies into the molecular 
mechanisms underlying the effects of specific nutrients are being revealed and 
found to intersect with many drug-target pathways known to be involved in cancer 
(Radimer, Bindewald et al. 2004; Werneke, Earl et al. 2004; Aggarwal and Shishodia 
2006).  In addition, individuals vary in their ability to metabolize specific nutrients, 
and this difference has been correlated with cancer risk (Curtin, Bigler et al. 2004; 
Shrubsole, Gao et al. 2004; Slattery, Neuhausen et al. 2004).   
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With the development and use of more targeted therapies, and with the 
increasing knowledge of how diet impacts the same pathways, consideration should 
be given to how diet and nutrients interact with cancer therapies.  Results from 
clinical trials have revealed that efficacy and toxicity of chemotherapeutics is 
individualized with few preclinical studies being predictive for these effects.  Better 
designed preclinical studies utilizing more than one mouse model, genetic 
background, and diet have the power to elucidate these variable circumstances, 
further improving the translational potential of mouse models by improving the 
predictive power and lowering the total cost of drug development. 
 
IMPROVING MODEL TRANSLATION TO HUMANS 
Mouse models have been used extensively to determine the underlying 
causes of many human diseases long before the genetic similarities between 
humans and mice were appreciated.  Their small size, relative affordability, short 
gestational times, and similarity to human organ systems have made the mouse a 
convenient model to study human disease. With the completion of the mouse and 
human genome sequence, it is now known that 40% of the human and mouse 
genomes can be directly aligned and greater than 80% of human genes have a 
direct orthologous gene in the mouse genome (Aggarwal and Shishodia 2006).  This 
data suggests that the mouse can serve not only as a physiological model for 
preclinical drug testing but can also be utilized as a model for studying the 
underlying genetic variation among individuals that modulates therapeutic response. 
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It is evident that traditional methods of pharmaceutical research are not 
adequate for painting the full picture of how a population of patients will respond to 
new therapeutics (Table 2).  The use of homogeneous ‘in vitro’ mouse models has 
proven to be economically inefficient when the total cost of drug development from 
target identification to clinical trial is considered. This is evident in the fact that a 
large number of drugs reaching clinical trials never achieve approval by the Food 
and Drug Administration (FDA).  As the identification of potential new 
pharmaceuticals increases, it is essential that parallel improvements be made in the 
use of preclinical models that accurately recapitulate the natural development and 
progression of human cancers. Similarly, models that incorporate host genetic 
variability and environmental conditions observed in clinical trials will improve the 
efficiencies and reduce the costs associated with drug development.  
 
CONCLUSIONS 
The sequencing of the human and model organism genomes is beginning to 
have a beneficial impact on the progress of drug discovery.  An individual’s genetic 
background and environment has the potential to significantly alter response to 
therapy or susceptibility to toxicity.  As the genome era continues to transform our 
understanding of the mechanisms behind human disease and response, the field of 
cancer therapeutics must incorporate new insights based upon models that 
accurately recapitulate the genetics and environmental circumstances of human 
cancers if the success of drug development is to improve. 
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 To investigate discordances between preclinical trials using mouse models 
and the efficacy of cancer therapeutics in clinical trials, the following study was 
designed to encompass complex factors that could potentially alter response to 
these treatments in humans, factors that are not commonly considered in animal 
studies.  The current study will address the influence of diet, model system, and 
genetic background on response to cancer therapy in an attempt to more closely 
resemble human studies, contributing to a new view of preclinical studies that are 
designed to better model complex patient populations and more accurately predict 
clinical outcomes. 
 Colorectal cancer (CRC) is the third most common type of cancer and 
accounts for about 10% of cancer-related deaths in the United States (ACS 2007).  
The American Cancer Society has linked environmental influences such as diet, 
alcohol consumption, smoking, and physical inactivity with higher incidences of 
CRC.  Common therapies for treating CRC include chemotherapy, radiation, and 
surgical removal of part or all of the large intestine.  Additionally, due to their 
reduced side effects and possible increased efficacy, molecule-targeted therapies 
have been developed and are being tested in preclinical and clinical trials.  One such 
therapy targets the EGFR/ERBB family of tyrosine kinase receptors, a pathway 
commonly deregulated in epithelial cancers (Harari, Allen et al. 2007).  
Epidermal growth factor receptor (EGFR) is a membrane bound tyrosine 
kinase receptor whose activation upon ligand binding and subsequent 
phosphorylation signals to downstream pathways involved in proliferation, 
differentiation, cell migration, angiogenesis and apoptosis.  Small molecule inhibitors 
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targeting the kinase domain and antibody inhibitors directed at the ligand binding 
domain of EGFR have been developed.  
 One small molecule inhibitor, AG1478, has so far been explored exclusively 
in preclinical trials.  In the following study, the efficacy of AG1478-mediated tumor 
reduction was evaluated in two mouse models for CRC, the ApcMin/+ and the 
azoxymethane (AOM) carcinogen models.  In an effort to improve preclinical 
modeling of human trials, a Western-style diet designed to model the diet commonly 
consumed in the United States was used in combination with the AG1478 inhibitor 
and compared to a standard diet resembling chow typically used to maintain mice 
and used in most previous preclinical studies.  Additionally, each mouse model was 
present on a distinct genetic background (ApcMin/+ on the C57BL/6J (B6) strain and 
AOM on the A/J (A) strain), as well as an F1 hybrid background (AB6F1) to elucidate 
the role of genetic background in the observed impact of diet on AG1478 efficacy. 
While diet should be a fundamental consideration when testing any therapy, 
dietary supplementation may have consequences as well.  Due to the increased 
popularity of dietary supplements, their roles in molecular pathways, including those 
involved in cancer, are being explored.  However, the impact of dietary supplements 
on current therapies for cancer is not known.  Both mouse models of CRC, as well 
as an in vitro model of two human CRC cell lines, Caco-2 and HCT116, was utilized 
to study the influence of dietary supplementation with calcium on AG1478 treatment 
of CRC.  Calcium is among the more commonly studied supplements in connection 
with CRC, and has numerous functions in the cell, interacting with many pathways 
involved in cancer including EGFR. 
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We provide evidence here that the diet consumed during cancer treatment, 
including the use of dietary supplements, may impact response to conventional 
therapies, and that understanding gene-environment-therapy interactions will be 
critical in developing and testing new therapies for CRC.   
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Table 1.  Mouse models of human cancer.  
Cancer Site Mouse Model 
 
Reference 
 
Brain 
medulloblastoma 
astrocytoma 
glioblastoma 
Ptc
+/-
;p53, GFAP-Cre;Rb
loxp/loxp
 
GFAP-v-src, GFAP-HRas 
NPcis 
(Weiss, Israel et al. 
2002) 
(Weiss, Israel et al. 
2002) 
(Reilly, Loisel et al. 2000) 
 
 
Breast 
low-grade mammary intraepithelial 
neoplasia 
high-grade mammary intraepithelial 
neoplasia 
papillary carcinoma 
human ductal carcinoma in situ 
(DCIS) 
 
MMTV-LTR/int3, MT/HGF 
C(3)1/SV40 tag, WAP/TGF 
MMTV-LTR/cyclin D1, MMTV-
PyV-mt 
MMTV-c-erb-B2 
 
(Cardiff, Anver et al. 
2000) 
(Cardiff, Anver et al. 
2000) 
(Cardiff, Anver et al. 
2000) 
(Cardiff, Anver et al. 
2000) 
 
Colon 
adenoma 
adenocarcinoma 
mucinous carcinoma 
 
Apc
min/+
, Apc
716
, Apc
1638N/+
 
Mlh1
-/-
;Apc
1638N/+
, Msh6
-/-
;Apc
1638N/+
, Msh3
-/-
;Apc
1638N/+ 
Tgfb
-/-
;Rag2
-/-
 
(Boivin, Washington et 
al. 2003) 
(Boivin, Washington et 
al. 2003) 
(Boivin, Washington et 
al. 2003) 
 
Lung 
bronchiolar neuroendocrine cell 
hyperplasia 
adenocarcinoma 
non-small-cell lung carcinoma 
 
Rb
+/-
;p53
-/-
 
Tg(Sp-C-LTag), Tg(CC10-Tag) 
K-ras
LSL
;p53, CC10-hASH1 
 
(Nikitin, Alcaraz et al. 
2004) 
(Nikitin, Alcaraz et al. 
2004) 
(Nikitin, Alcaraz et al. 
2004; Kim, Jackson et al. 
2005) 
 
Prostate 
low-grade prostatic intraepithelial 
neoplasia (LGPIN) 
high-grade intraepithelial neoplasia 
(HGPIN) 
invasive carcinoma 
metastasis 
 
 
PB-Ras, Nkx3.1
-/-
 
ARR2PB-Skp2 
LPB-SV40 Tag (Lady model) 
Pb-Cre4;PTEN
loxp/loxp
,  
LPB-Tag;ARR2PB-hepsin,  
TRAMP model 
 
 
(Kasper 2005) 
(Kasper 2005) 
(Kasper 2005) 
(Kasper 2005) 
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Table 2.  Comparison of models for preclinical testing.  
In vivo  In vitro 
xenograft engineered population 
mirrors human 
histopathological 
progression, intact immune 
system, host tumor 
microenvironment retained 
Pros 
 
cost and time 
efficiency, 
high throughput 
 
cost and time 
efficiency 
(relative to other 
in vivo systems) 
 
incorporates 
genetic 
modifiers 
Cons 
 
contamination, 
genetic selection, 
lack of 
physiological 
relevance 
 
lack immune 
system, tumor 
microenvironment 
different from 
host, inability to 
detect genetic 
modifiers 
patents, higher direct cost, 
long timeline, genotyping, 
lower throughput 
Best 
Use of 
Model 
high throughput 
screening for initial 
target identification 
validation of drug 
access to target 
pharmacological and 
toxicological preclinical 
testing 
Access 
to Model 
ATCC, 
Cambrex/Clonetics 
MMHCC, Jackson Laboratories, Harlan, Taconic 
Charles River Laboratories 
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Abstract 
 
 Molecule-targeted therapies are some of the most promising cancer 
therapeutics being developed today.  Many new drugs are either in preclinical and 
clinical trials, or have been approved for use in the clinic.  Some of the most widely 
investigated molecule-targeted therapies are for the epidermal growth factor 
receptor (EGFR), which is often deregulated in epithelial cancers.  While EGFR 
inhibitors have shown efficacy against some cancers, clinical results are frequently 
less encouraging than the preclinical trials they were based upon.  We investigated 
potential causes for these inconsistencies by examining the effect of model 
selection, genetic background and diet on preclinical results in an effort to design 
better preclinical studies that more accurately predict human therapeutic response. 
The efficacy of the small molecule, EGFR inhibitor AG1478 was tested using two 
mouse models of human colorectal cancer (CRC), ApcMin/+ and azoxymethane 
(AOM).  Furthermore, three genetic backgrounds were used while the mice were 
maintained on either a standard mouse chow (STD) or Western-style diet (WD).  We 
found that the efficacy of AG1478 varied by model, background and diet.  AG1478 
has significant anti-tumor activity in the ApcMin/+model on a C57BL/6J (B6) 
background with STD or the AOM model on an A/J (A) background with a WD.  
However, no anti-tumor activity was observed in the ApcMin/+ model on WD or the 
AOM model on STD.  When an F1 hybrid background between B6 and A is used, 
AG1478 is effective in the ApcMin/+ model with either STD or WD, while having no 
activity in the AOM model with either diet.  We also found that WD increases tumor 
number when compared to STD in both sexes of the ApcMin/+ model, but only in 
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females in the AOM model.  Our results strongly indicate that model-dependent 
interactions between genetic background and diet can dramatically impact the 
apparent success of pre-clinical studies, and suggest that pre-clinical therapeutic 
trials should be designed to better model the heterogeneous patient population. 
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Introduction 
 
 While many new promising therapies are being approved for cancer 
treatment, it is becoming clear that their efficacy in clinical trials is not reflective of 
that predicted in preclinical studies.  An analysis of published Phase 1 clinical trials 
from 1991-2002 revealed that only 3.8% of patients showed a significant clinical 
response (Roberts, Goulart et al. 2004).  Among the most prevalent cancers, 
colorectal cancer (CRC) had the lowest response rate of 1.3%, necessitating an 
investigation into how preclinical studies can be improved.  Animal models used in 
preclinical studies have been useful in predicting targets for these new therapies, but 
they are rarely designed to incorporate factors faced in human clinical trials, such as 
genetic background and diet, possibly contributing to the inconsistencies observed 
when moving a drug from preclinical to clinical studies.   
CRC is the third most prevalent cancer and accounts for an estimated 10% of 
cancer-related deaths in the United States (ACS 2007).  Increased survival in recent 
years can be attributed to improved screening and awareness of environmental 
factors associated with CRC such as smoking, alcohol consumption, physical 
inactivity, and diets high in fat and red meat and low in essential nutrients.   
Several mouse models have been developed for use in studying the etiology 
of CRC and to improve investigation of pre-clinical therapies; the most widely used 
are the ApcMin/+ and azoxymethane (AOM)-treated mouse models (Druckrey 1970; 
Su, Kinzler et al. 1992; Steele, Moon et al. 1994; Lipkin 1997).   
The APC (adenomatous polyposis coli) gene encodes a tumor suppressor 
protein that is responsible for the degradation of -catenin (CATNNB) and 
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prevention of WNT-mediated signal transduction. When APC is mutated, like the 
germ-line APC mutations responsible for familial adenomatous polyposis (FAP), 
CATNNB is not degraded, permitting it to function as a transcriptional co-activator 
with the TCF (T-cell factor) family of transcription factors and leading to cellular 
transformation.  This results in hundreds to thousands of intestinal adenomas in 
humans.  When left untreated, these adenomas can develop into CRC.  APC is also 
somatically mutated in about 85% of sporadic or non-familial CRCs (Jen, Powell et 
al. 1994). Although there are subtle differences between FAP patients and ApcMin/+ 
mice, like the distribution of polyps, which are largely in the colon in humans but 
small intestine in mice, the ApcMin/+ model has been widely used to test CRC 
response to therapeutics because the identical pathway is perturbed in both humans 
and mice. 
Another model commonly used to study CRC promotion and treatment is the 
AOM model.  Since mice rarely develop spontaneous colon tumors, the colon-
specific carcinogen AOM can be used to induce CRC.  AOM is an alkylating agent 
that forms DNA adducts resulting in mutations primarily resulting in tumors in the 
colon, that are APC-mediated like in the ApcMin/+ model (Takahashi and 
Wakabayashi 2004). 
CRC results from sequential genetic mutations (Kinzler and Vogelstein 1996), 
with many potential anti-cancer targets.  One such target is the epidermal growth 
factor receptor (EGFR).  EGFR signaling is deregulated in up to 50% of epithelial 
cancers (Harari, Allen et al. 2007).  Numerous agents have been developed to target 
EGFR that are currently being investigated in clinical trials or have been approved 
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for use in the clinic.  These therapies include small molecule inhibitors that target the 
kinase domain and blocking antibodies against the ligand-binding domain.  
 Previous studies have shown that ApcMin/+ tumors display increased EGFR 
activity, and that treatment with small molecule EGFR inhibitors results in a 
significant decrease in tumor incidence in these mice (Torrance, Jackson et al. 2000; 
Roberts, Min et al. 2002; Moran, Hunt et al. 2004).  In addition, though preclinical 
studies have yet to show efficacy of EGFR-inhibition in the AOM model, AOM-
induced tumors show increased EGFR activity (Malecka-Panas, Fligiel et al. 1996), 
therefore it is reasonable to hypothesize that this model will also respond to EGFR-
targeted treatment.  Although many studies have provided evidence for the potential 
efficacy of EGFR-targeted treatment of CRC, preclinical evidence has not accurately 
predicted clinical outcomes.  One possible issue with preclinical trials is the 
oversimplification of modeling human trials in mice.   
Currently a Western-style diet, commonly consumed in North America and 
Europe, is characterized by high fat and low amounts of fruits and vegetables.  
Studies have linked this type of diet to increased cancer incidence, including CRC. 
Modeling the Western-style diet in mice, with increased fat, decreased Vitamin D, 
and decreased calcium, results in increased hyperproliferation in pancreatic, 
prostate and mammary epithelial cells (Xue, et al. 1999).  The same diet induces 
hyperproliferation in intestinal epithelial cells of wild-type C57BL/6 (B6) mice 
(Newmark, et al. 2001).  Further modification of the diet to include decreased levels 
of folate and other nutrients essential for DNA methylation induces adenomas and 
carcinomas in these mice.   
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 In addition to the potential for diet to influence tumorigenesis, it is also evident 
that genetic background is important.  As with human CRC, susceptibility to AOM-
induced tumors is dependent on genetic background; tumor incidence and size 
varies across mouse strains (Papanikolaou, Wang et al. 1998; Nambiar, Girnun et 
al. 2003; Bissahoyo, Pearsall et al. 2005).  A/J (A) mice, for example, are highly 
susceptible to AOM-induced tumors whereas C57BL/6J (B6) mice are resistant.  
Likewise, tumor incidence in the ApcMin/+ model is greatly dependent on mouse 
strain, B6 mice bearing significantly more tumors compared to F1 mice with less 
susceptible strains AKR and A (Steffensen and Alexander 2006; Kwong, Shedlovsky 
et al. 2007).   
With the knowledge that genetic background and diet independently and 
differentially influence tumor incidence in mice and in humans, it is reasonable to 
expect that they may also be important factors contributing to the variability of 
EGFR-targeted therapies in human clinical trials. Thus, we investigated the 
preclinical efficacy of the small molecule EGFR inhibitor AG1478 to treat CRC with 
different diets and genetic backgrounds. We provide evidence that the success of 
such a drug in reducing tumor number in preclinical trials is largely dependent 
model, genetic background and diet.   
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Materials and Methods 
Experimental design 
 Equal numbers of male and female A/J (A) mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and maintained on 5058 mouse chow 
(LabDiet, Richmond, Indiana).  Additionally, male and female A X C57BL/6J (B6) F1 
(AB6F1) hybrid mice were generated in house.  At four months of age mice were 
injected weekly with AOM (10mg/kg body weight) for six weeks (Fig. 1).  One week 
prior to the first AOM injection, mice were moved to a standard diet (STD; AIN-93G 
from Research Diets, New Brunswick, New Jersey), while one week after the last 
AOM injection, mice were randomly assigned to one of two diets, STD or Western 
(WD; D12079B from Research Diets, New Brunswick, New Jersey) (Table 3), with or 
without 144mg/kg chow of EGFR-inhibitor AG1478 (LC Labs, Woburn, MA).  WD is 
nutritionally matched with the STD except for increased fat and reduced fiber, 
calcium and vitamin D, more consistent with the diets consumed by people in North 
America.  Mice were maintained on their respective diet for 12 weeks before being 
euthanized with CO2.  Colons were dissected, flushed with phosphate-buffered 
saline (PBS), splayed on bibulous paper and scored for tumor number, diameter and 
location (in mm from distal end).   
 B6-ApcMin/+ males were mated to wild-type B6 or A females to generate 
AB6F1 hybrids, and progeny containing the ApcMin allele were weaned at 3 weeks of 
age and assigned to STD or WD, with or without AG1478 (Fig. 1).  After 9 weeks of 
treatment mice were euthanized and the entire intestinal tract was flushed with PBS 
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and splayed on bibulous paper.  The intestine was divided into 4 sections: small 
intestine (duodenum, jejunum, and ileum) and large intestine (colon).   
 Body weights were monitored biweekly for the AOM model and weekly for the 
Apc
Min/+ model.  Blood glucose was measured using a FreeStyle Glucose meter at 
the time at euthanasia. All mice were housed in an AAALAC approved-facility and 
provided chow and water ad libitum.  All experiments were approved by the 
Institutional Animal Care and Use Committee. 
 
Phosphatase inhibitor treatment and protein extraction 
 Prior to euthanasia mice were injected with 10μl/g body weight of 5mM 
phosphatase inhibitor sodium orthovanadate (activated with 50mM hydrogen 
peroxide 15 minutes prior to use) (Ruff, Chen et al. 1997).  Five minutes after 
injection livers were dissected and snap frozen in liquid nitrogen.  Total proteins 
were extracted with lysis buffer containing 10mM Tris-HCl (pH 8), 100mM NaCl, 
1mM EDTA, 1mM EGTA, 1mM NaF, 1% NP-40, 10% Glycerol, 0.1% SDS, 0.5% 
Sodium deoxycholate, 1mM PMSF, 10μg/ml leupeptin, 10μg/ml aprotinin, 1mM 
Na3VO4, and 1mM NaF.  A Bradford protein assay was used to determine protein 
concentration (Bio-Rad, Hercules, CA). 
   
Western blot analysis 
 Thirty μg of liver protein was loaded onto 4-15% gradient Tris-HCl gels (Bio-
Rad, Hercules, CA).  After transfer to PVDF membranes for one hour, membranes 
were blocked for one hour in 5% BSA/TBS (0.1% Tween) for rabbit anti-pEGFR 
 34
1068 antibody, anti-pAKT, and anti-pMAPK44/42  (Cell Signaling, Danvers, MA) or 
5% milk/TBST for sheep anti-EGFR (Millipore, Billerica, MA) and mouse anti-actin 
(Sigma, St.Louis, MO) antibodies.  Membranes were incubated with primary 
antibody overnight at 4°C.  Antibodies against pEGFR, pAKT, and pMAPK44/42 
were diluted 1:2,000 in 1% BSA/TBST, EGFR diluted 1:5,000 and -actin diluted 
1:10,000 in 5% milk/TBST.  After washing, membranes were incubated with 
secondary antibodies for one hour at room temperature.  Secondary antibodies 
(Jackson ImmunoResearch, West Grove, PA) were diluted 1:20,000 in the same 
solution as the primary antibody.  SuperSignal West Dura Extended Duration ECL 
(Pierce, Rockford, IL) was used for visualization of proteins.  Three replicates were 
performed per gender, treatment and model/strain. 
 
Statistical analysis 
 Body weights at end of treatment, tumor number and tumor size data were 
analyzed using non-parametric Mann Whitney (Prism 4.0, GraphPad Software, Inc.).   
 Linear mixed models were performed to assess whether diet (STD, WD) and 
AG1478 inhibitor were associated with glucose levels.  Models were evaluated with 
mouse strain (A, B6, AB6F1) treated as a random effect and mouse model (AOM, 
Apc
Min/+) treated as a fixed effect. Tests for interaction effects were performed to 
assess whether any effect of diet, and inhibitor on glucose levels were independent.  
In addition, subset analyses were performed that focused specifically on the F1 
strain.  Using results from the F1 strain, tests of main effects (for diet, inhibitor and 
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model) and interactions were performed based using mice with the same genetic 
background. 
 
Results 
Western-style diet and AG1478 impact on general health 
 The effects on general health of a diet designed to model that typically 
consumed by people in North America (WD) was compared to a diet typical of that 
used for most pre-clinical studies (STD).  Unlike previous reports (Newmark, Lipkin 
et al. 1991; Richter, Newmark et al. 1995), body weight was not significantly affected 
by diet (Fig. 2).  Similarly, treatment with the EGFR inhibitor did not alter body 
weight.  Irrespective of diet, AB6F1 mice consistently weighed more than their A or 
B6 inbred strains, with the difference being most evident in the AOM model. 
 Blood glucose was also measured at the end of diet treatment (Fig. 3).  The 
AOM model was strongly associated (p < 0.0001) with decreased glucose levels 
compared to ApcMin/+ mice.  Evidence for a trend (p =0.067) was found between 
presence of inhibitor and decreased glucose levels while no evidence was found for 
an association between diet and glucose levels.  Significant evidence for an 
interaction between inhibitor and mouse model (p = 0.012) on glucose levels was 
observed.  No evidence for any interaction between diet and inhibitor were detected 
on glucose levels. 
Results restricted to the AB6F1 strain found strong evidence for the AOM 
model being associated with decreased glucose levels (p < 0.0001).  Interestingly, 
evidence for an interaction between mouse model and inhibitor was detected (p = 
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0.012) that suggested presence of inhibitor was associated with modestly higher 
glucose levels in AOM and strongly lower glucose levels in ApcMin/+ compared to 
absence of inhibitor.  
 
Western-style diet is associated with increased tumor growth 
 
 Consistent with previous reports, treatment with WD significantly increased 
tumor incidence compared to STD (Fig. 4).  However, the effect on tumor incidence 
by diet was not uniform across backgrounds and models.  While WD increased 
tumor incidence in B6-ApcMin/+, AB6F1-ApcMin/+, and female A mice treated with 
AOM, WD had no significant impact on tumor number in A males or either sex from 
AB6F1 treated with AOM.  In addition to influencing tumor number, WD also resulted 
in increased size of small intestinal tumors in the ApcMin/+ model on both genetic 
backgrounds (Fig. 5).  No diet affect on tumor size was observed with the AOM 
model. 
 
Tumor reduction by EGFR inhibition is diet, background and model dependent 
 
 Confirming previous reports (Torrance, Jackson et al. 2000; Roberts, Min et 
al. 2002; Moran, Hunt et al. 2004), we found that pharmacologic inhibition of EGFR 
decreased small intestinal tumor number in the ApcMin/+ model, when on STD (Fig. 
4).  However, when EGFR-targeted therapy is performed on WD, no significant 
change in tumor number is observed.  AG1478 does not reduce colonic tumor 
number on either diet in APCMin/+ mice.   Conversely, AG1478 does significantly 
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reduce colonic tumor number in A mice treated with AOM when maintained on the 
WD, but not on the STD.  
On the AB6F1 background, no significant effect on tumor number was 
observed by EGFR inhibition in the AOM model on either diet (Fig. 4).  Conversely, 
AG1478 reduced tumor number in the small intestine of ApcMin/+ mice maintained on 
either diet.  Similar to the B6 inbred strain, the number of colonic tumors in AB6F1-
Apc
Min/+ mice is not affected by AG1478 on either diet.   
 Consistent with an effect on tumor growth, AG1478 also reduced tumor size 
in AB6F1-ApcMin/+ mice maintained on either diet.  Additionally, tumors in the colon 
were also reduced in size when AB6F1-ApcMin/+ mice were maintained on STD (Fig. 
5).  Unlike the impact observed on tumor number, AG1478 reduces tumor size in 
B6-ApcMin/+ mice maintained on WD but not STD. Conversely, an effect of AG1478 
in A mice treated with AOM was observed when maintained on STD but not WD.   
 
EGFR signaling is differentially impacted by AG1478 depending on diet, 
background, model and sex 
 
 To evaluate the level of EGFR inhibition, which should reflect the relative 
therapeutic efficacy, reduction in phospho (p)-EGFR activity as well as the 
downstream signal mediators pAKT, and p44/42 MAPK (pERK1/2) was measured 
by western analysis.  Analyses were performed by sex since sex-dependent effects 
were observed in overall tumor number (Appendix) and in response to WD in A 
female mice treated with AOM. 
 Although B6-ApcMin/+ mice maintained on STD respond to AG1478-mediated 
tumor inhibition, females show no inhibition of EGFR baseline activity in response to 
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AG1478 treatment; males show a response to AG1478 as reflected by lower pEGFR 
and pAKT levels (Fig. 6).  Interestingly, WD is associated with low levels of pAKT 
and pERK1/2 in females and low pAKT in males compared to STD. 
 In AB6F1-ApcMin/+ mice, AG1478-mediated tumor inhibition is observed on 
both STD and WD.  Similarly, AG1478 is associated with decreased pEGFR in both 
males and females on the STD.  However, AG1478 does not appear to be 
associated with inhibition of EGFR signaling in mice maintained on the WD.  WD 
alone appears to be associated with increased EGFR in both males and females, 
but has opposing effects on pEGFR, increasing pEGFR in females while decreasing 
pEGFR in males.  WD alone also appears to be associated with decreased pAKT 
and pERK in males.   
 In AOM-treated mice AG1478 reduces tumor number when combined with 
WD, and likewise, inhibition of pEGFR is observed in both males and females while 
reduced pERK is observed only in males.  In addition, WD appears to induce EGFR 
activity compared to STD.  Interestingly, females on the STD show higher pAKT and 
pERK activity when treated with AG1478 compared to no treatment. 
 AG1478 was not effective in reducing tumor growth in AB6F1 mice treated 
with AOM, and this is reflected in the absence of an effect on EGFR signaling.  On 
both diets, AG1478 appears to actually induce rather than inhibit EGFR activity.  
Additionally, WD alone does not induce EGFR activity in AB6F1 mice as it does in A 
mice, but rather may reduce EGFR downstream signaling. 
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Discussion 
 Designing preclinical studies for cancer therapeutics that more closely model 
conditions faced in human clinical trials will be necessary to better predict drug 
efficacy.  In the current study we investigated the efficacy of a small molecule EGFR 
inhibitor AG1478 for treatment of CRC using two mouse models, each on a distinct 
inbred strain and a common F1 genetic background to model genetic heterogeneity 
of the CRC patient population.  In addition to using a standard mouse diet we also 
investigate the impact of modeling a Western-style human diet on this therapy.   
We observed a different response to AG1478 for each of the four 
combinations of model and genetic background.  Within the inbred strains, AG1478 
inhibits tumor number when combined with the STD in the B6-ApcMin/+ model and 
with the WD in A mice treated with AOM.  In the AB6F1 background AG1478 
reduces tumor number on both diets in the ApcMin/+ model but does not reduce tumor 
number on either diet in the AOM model.  Whether using an inbred or F1 hybrid 
background, we essentially observe opposing results between the two models. In 
some cases where tumor number reduction is not observed, reduction in tumor size 
is observed suggesting that EGFR inhibition does have some efficacy even when 
tumor number is unaffected.  
 AG1478 was also associated with lower blood glucose levels in AB6F1-
Apc
Min/+ mice irrespective of diet, corresponding to the tumor reduction observed in 
these mice.  Likewise, AG1478 was not associated with lower glucose levels in 
AB6F1 mice treated with AOM, consistent with a lack of tumor response to AG1478.  
The connection between glucose and EGFR activity is not clear, but studies have 
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suggested that there is a requirement for EGFR in glucose metabolism, and 
decreased glucose uptake in tumors has been associated with use of EGFR-
inhibitors (Su, Bodenstein et al. 2006).  However, in one study involving diabetic 
mice, AG1478 was not associated with changes in blood glucose (Benter, Yousif et 
al. 2005).  Further studies will be required to determine if blood glucose levels are 
associated with efficacy of EGFR-targeted therapy. 
 We also observed a differential response to diet alone.  WD increased tumor 
number and size in some mice and increased EGFR signaling.  Studies have shown 
that the EGFR pathway is influenced by many diet-related factors, including dietary 
and herbal supplements (Aggarwal and Shishodia 2006) and fatty acids (Vacaresse, 
Lajoie-Mazenc et al. 1999; Moral, Solanas et al. 2003).  Unsaturated fatty acids were 
shown to activate EGFR signaling in a rodent model for breast cancer as well as 
human endothelial cells.  In the rodent model, a diet high in polyunsaturated fat (corn 
oil) increased EGFR activity while monounsaturated fat (olive oil) decreased activity.  
In endothelial cells unsaturated fat in the form of oleic acid and polyunsaturated fatty 
acids induced EGFR activity and downstream MAPK activation, possibly through 
direct interaction with the receptor, and this induction depended on degree of 
saturation.   
 Since it is apparent that genetic background alone may not account for the 
contradictory response to AG1478 other factors should be considered.  The B6-
Apc
Min/+ and AOM-treated A mouse models also have differential susceptibility to 
diet-induced obesity with the B6 background being susceptible, while the A 
background is resistant.  Furthermore, the distribution of tumors (entire intestinal 
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tract versus colon only), age at onset of diet treatment (3 weeks versus 6 months), 
length of diet treatment (9 versus 12 weeks), initiating mutational events (Apc versus 
Catnnb) and potentially microflora may also contribute to model-dependent 
differences in response to AG1478.  Each of these differences, particularly 
susceptibility to obesity, distribution of tumors and microflora, likely contribute to 
strain and model differences in metabolism of dietary and therapeutic agents. 
 Finally, sex-dependent influences on tumor incidence and tumor response to 
both diet and AG1478 treatment exist.  Overall tumor number is higher in AOM-
treated female AOM mice on A or AB6F1 backgrounds and female AB6F1-ApcMin/+ 
mice (small intestine only) but lower in female B6-ApcMin/+ colons compared to males 
(Appendix).  In addition, only females were vulnerable to WD-induced tumors in the 
AOM model.  For this reason AG1478 impact on EGFR signaling was stratified 
according to sex in addition to model and strain.   
 In the liver AG1478 impacts EGFR signaling only when combined with 
specific diet, strain and model combinations, and is not perfectly concordant with the 
inhibition of tumor growth observed.  For example, B6-ApcMin/+ females show no 
AG1478-mediated change in EGFR activity despite having a reduction in tumors on 
STD.  Also, AG1478 is effective on WD in AB6F1-ApcMin/+ mice but this is not 
reflected in EGFR signaling in the liver.  While the inability to impact EGFR signaling 
in AOM-treated AB6F1 mice does correspond to the lack of tumor inhibition 
observed, it is not clear why AG1478 is apparently not being metabolized on either 
diet in these mice. 
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 Circumstances where AG1478 reduces EGFR activity but not tumor growth 
may be indicative of the presence of EGFR-independent tumors.  We also must 
consider that, while AG1478 is metabolized in the liver, EGFR signaling here may 
not always reflect an equivalent impact on EGFR signaling in the tumors.  
Additionally, dietary components or crosstalk with other pathways may interfere with 
AG1478 efficacy or our ability to observe its impact on signaling.   
 Future studies investigating the role of sex on differential responses to diet 
and the potential role of specific dietary components will be necessary.  However, 
we can conclude from the results presented here that a genetic-environment-therapy 
relationship exists and must be considered when designing preclinical studies.  
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Figure 1.  Experimental design.  At weaning (ApcMin/+) or 1 week following the last 
carcinogen treatment (AOM) mice were randomly assigned to a Standard (STD) or 
Western-style (WD) base diet, with or without small-molecule EGFR inhibitor 
AG1478. 
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 Table 3.  Comparison of diet compositions.    
17 20 Protein (kcal%) 
0.21% 0 Cholesterol 
29 10 Sucrose (kcal%) 
43 64 Carbohydrate (kcal%) 
100 1000 Vitamin D (IU/kg) 
0.5 5 Calcium (g/kg) 
2 5 Fiber (%) 
41 
Milk, corn oil 
16 
Soybean oil 
Fat (kcal%) 
Fat Type 
4.7 4 Calories (kcal/g) 
Western Diet 
(WD) 
Standard Diet 
(STD) 
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Figure 2.  Comparison of body weight change for mice from the ApcMin/+ (a) and 
AOM (b) models. Mice were maintained on STD () or WD (), without (left panels) 
or with (right panels) AG1478.  
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Figure 3.  Blood glucose measurements in the ApcMin/+ and AOM models.    
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Figure 4.  Effect of STD and WD on AG1478-mediated tumor number reduction in 
(a) ApcMin/+(B6 and AB6F1) small intestine and colon and (b) AOM (A and AB6F1) 
colon, expressed as a percent of STD treatment.  [n  10 mice for ApcMin/+ (B6), 26 
for ApcMin/+ (AB6F1), 18 for AOM (A), and 11 for AOM (AB6F1).]    
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Figure 5.  Effect of STD and WD on AG1478-mediated tumor size reduction in (a) 
Apc
Min/+(B6 and AB6F1) small intestine and colon and (b) AOM (A and AB6F1) 
colon, expressed as a percent of STD treatment.  [n  448 tumors for APCMin/+(B6) 
small intestine; 572 for APCMin/+(AB6F1) small intestine; 11 for APCMin/+(B6) colon; 
12 for APCMin/+(AB6F1) colon; 62 for AOM (A/J) colon; 25 for AOM (F1) colon]   
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Figure 6.  Western blot analysis of AG1478 activity.  Mice maintained on a STD or 
WD, with or without AG1478, were injected with phosphatase inhibitor prior to 
euthanasia.  EGFR activation and downstream EGFR signaling were measured in 
liver protein lysates from APCMin/+ (a) and AOM (b) mice, separately for each strain 
and sex.   
 
 55
  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
pEGFR
EGFR
pAKT
p44/42 MAPK
-actin
 -    +     -    +     -    +    -    +
STD WDSTDWD
Female Male
a) ApcMin/+ 
B6
 -    +     -    +     -    +    -    +
STD WDSTDWD
Female Male
AB6F1
pEGFR
EGFR
pAKT
p44/42 MAPK
-actin
 -    +     -    +     -    +    -    +
STD WDSTDWD
Female Male
A
 -    +     -    +     -    +    -    +
STD WDSTDWD
Female Male
AB6F1
AG1478
AG1478
b) AOM
 56
REFERENCES 
 
American Cancer Society.  Cancer Facts & Figures.  Atlanta:  American Cancer 
Society; 2007. 
 
Aggarwal, B. B. and S. Shishodia (2006). "Molecular targets of dietary agents for 
prevention and therapy of cancer." Biochem Pharmacol 71(10): 1397-421. 
 
Benter, I. F., M. H. Yousif, et al. (2005). "Diabetes-induced renal vascular 
dysfunction is normalized by inhibition of epidermal growth factor receptor 
tyrosine kinase." J Vasc Res 42(4): 284-91. 
 
Bissahoyo, A., R. S. Pearsall, et al. (2005). "Azoxymethane is a genetic background-
dependent colorectal tumor initiator and promoter in mice: effects of dose, 
route, and diet." Toxicol Sci 88(2): 340-5. 
 
Druckrey, H. (1970). Colonic Carcinomas by 1,2-Dialkylhydrazines and 
Azoxyalkanes. Springfield, IL, Charles C Thomas. 
 
Harari, P. M., G. W. Allen, et al. (2007). "Biology of interactions: antiepidermal 
growth factor receptor agents." J Clin Oncol 25(26): 4057-65. 
 
Jen, J., S. M. Powell, et al. (1994). "Molecular determinants of dysplasia in colorectal 
lesions." Cancer Res 54(21): 5523-6. 
 
Kinzler, K. W. and B. Vogelstein (1996). "Lessons from hereditary colorectal cancer." 
Cell 87(2): 159-70. 
 
Kwong, L. N., A. Shedlovsky, et al. (2007). "Identification of Mom7, a novel modifier 
of Apc(Min/+) on mouse chromosome 18." Genetics 176(2): 1237-44. 
 
Lipkin, M. (1997). "New rodent models for studies of chemopreventive agents." J 
Cell Biochem Suppl 28-29: 144-7. 
 
Malecka-Panas, E., S. E. Fligiel, et al. (1996). "Azoxymethane enhances ligand-
induced activation of EGF receptor tyrosine kinase in the colonic mucosa of 
rats." Carcinogenesis 17(2): 233-7. 
 
Moral, R., M. Solanas, et al. (2003). "Modulation of EGFR and neu expression by n-
6 and n-9 high-fat diets in experimental mammary adenocarcinomas." Oncol 
Rep 10(5): 1417-24. 
 
 
 
 57
Moran, A. E., D. H. Hunt, et al. (2004). "Apc deficiency is associated with increased 
Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ 
mice." J Biol Chem 279(41): 43261-72. 
 
Nambiar, P. R., G. Girnun, et al. (2003). "Preliminary analysis of azoxymethane 
induced colon tumors in inbred mice commonly used as transgenic/knockout 
progenitors." Int J Oncol 22(1): 145-50. 
 
Newmark, H. L., M. Lipkin, et al. (1991). "Colonic hyperproliferation induced in rats 
and mice by nutritional-stress diets containing four components of a human 
Western-style diet (series 2)." Am J Clin Nutr 54(1 Suppl): 209S-214S. 
 
Papanikolaou, A., Q. S. Wang, et al. (1998). "Azoxymethane-induced colon tumors 
and aberrant crypt foci in mice of different genetic susceptibility." Cancer Lett 
130(1-2): 29-34. 
 
Richter, F., H. L. Newmark, et al. (1995). "Inhibition of Western-diet induced 
hyperproliferation and hyperplasia in mouse colon by two sources of calcium." 
Carcinogenesis 16(11): 2685-9. 
 
Roberts, R. B., L. Min, et al. (2002). "Importance of epidermal growth factor receptor 
signaling in establishment of adenomas and maintenance of carcinomas 
during intestinal tumorigenesis." Proc Natl Acad Sci U S A 99(3): 1521-6. 
 
Roberts, T. G., Jr., B. H. Goulart, et al. (2004). "Trends in the risks and benefits to 
patients with cancer participating in phase 1 clinical trials." Jama 292(17): 
2130-40. 
 
Ruff, S. J., K. Chen, et al. (1997). "Peroxovanadate induces tyrosine phosphorylation 
of multiple signaling proteins in mouse liver and kidney." J Biol Chem 272(2): 
1263-7. 
 
Steele, V. E., R. C. Moon, et al. (1994). "Preclinical efficacy evaluation of potential 
chemopreventive agents in animal carcinogenesis models: methods and 
results from the NCI Chemoprevention Drug Development Program." J Cell 
Biochem Suppl 20: 32-54. 
 
Steffensen, I. L. and J. Alexander (2006). "Impact of genetic background on 
spontaneous or 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-
induced intestinal tumorigenesis in Min/+ mice." Cancer Lett 240(2): 289-96. 
 
Su, H., C. Bodenstein, et al. (2006). "Monitoring tumor glucose utilization by positron 
emission tomography for the prediction of treatment response to epidermal 
growth factor receptor kinase inhibitors." Clin Cancer Res 12(19): 5659-67. 
 58
Su, L. K., K. W. Kinzler, et al. (1992). "Multiple intestinal neoplasia caused by a 
mutation in the murine homolog of the APC gene." Science 256(5057): 668-
70. 
 
Takahashi, M. and K. Wakabayashi (2004). "Gene mutations and altered gene 
expression in azoxymethane-induced colon carcinogenesis in rodents." 
Cancer Sci 95(6): 475-80. 
 
Torrance, C. J., P. E. Jackson, et al. (2000). "Combinatorial chemoprevention of 
intestinal neoplasia." Nat Med 6(9): 1024-8. 
 
Vacaresse, N., I. Lajoie-Mazenc, et al. (1999). "Activation of epithelial growth factor 
receptor pathway by unsaturated fatty acids." Circ Res 85(10): 892-9. 
 
 Xue, L., M. Lipkin, et al. (1999). "Influence of dietary calcium and vitamin D on diet-
induced epithelial cell hyperproliferation in mice." J Natl Cancer Inst 91(2): 
176-81. 
 
  
 
 
  
CHAPTER 3 
 
AG1478 AND CALCIUM
 60
Dietary calcium supplementation enhances therapeutic efficacy of 
EGFR blockade against colorectal cancer 
 
Erica S. Rinella 
a
, Eric Bankaitis, and David W. Threadgill 
a,b,
* 
 
a
 Department of Genetics and Curriculum in Genetics and Molecular Biology, 
University of North Carolina, Chapel Hill, NC 27599 USA 
b
 Lineberger Cancer Center, Center for Gastrointestinal Biology and Disease, 
Carolina Center for Genome Sciences, and Center for Environmental Health and 
Disease, University of North Carolina, Chapel Hill, NC 27599 USA 
 
** Correspondence: David Threadgill 
   Department of Genetics, CB#7264 
   University of North Carolina 
   Chapel Hill, NC 27599 
   E-mail: dwt@med.unc.edu 
   Tel: (919) 843-6472 
   Fax: (919) 966-3292 
Keywords:    
Running Title:  
 
 
 
 61
Abstract 
The role of calcium as a dietary supplement that contributes to colorectal 
cancer (CRC) susceptibility has been extensively investigated because of 
epidemiological links between intake of calcium and CRC incidence.  Many 
preclinical and clinical studies have provided evidence for its efficacy in preventing 
CRC.  However, the potential impact of calcium after cancers arise and, in particular, 
on conventional therapies for CRC is not known.  In this study we used in vitro and 
in vivo models of CRC to investigate the impact of a western-style diet low in calcium 
(0.05%) versus a similar diet but high in calcium (5%) on EGFR-targeted therapy, 
with two human CRC cell lines, Caco-2 and HCT116, and two mouse models 
Apc
Min/+ and azoxymethane (AOM).  We found that calcium supplementation 
combined with the small molecule EGFR inhibitor AG1478 results in an additive 
effect on tumor growth inhibition, compared to either agent alone, in all of the four 
model systems.  We also reveal that gender and toxicity should be given careful 
consideration in future studies investigating the role of dietary supplements alone or 
with cancer therapies.
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Introduction 
Lifestyle, particularly diet, has been shown to have a significant impact on 
cancer, contributing to an estimated one-third of all cancer deaths in the U.S. (ACS 
2007).  The Western diet, common to North American and European countries, is 
characterized by high fat and cholesterol and low levels of essential nutrients, and 
has been linked with increased incidence of colorectal cancer (CRC).  
Modeling the human Western diet in mice with increased fat, decreased 
vitamin D, and decreased calcium results in increased hyperproliferation in 
pancreatic, prostate, and mammary epithelial cells (Xue, Lipkin et al. 1999).  
Repletion with vitamin D and calcium suppressed this growth.  The same diet 
induced hyperproliferation in intestinal epithelial cells of wild-type C57BL/6J (B6) 
mice (Newmark, Yang et al. 2001).  Further modification of the diet to include 
decreased levels of folate and other nutrients essential for DNA methylation induced 
adenomas and carcinomas in these mice. 
In an effort to augment diet, nutritional supplements have been on the rise in 
recent years.  In addition, evidence has reached the general population that some 
dietary supplements may be beneficial in treating or preventing cancer.  Likewise, an 
estimated fifty percent of cancer patients take some form of dietary supplementation 
(Werneke, Earl et al. 2004).  However, the impact of these supplements on cancer 
and, perhaps more importantly, their potential interaction with conventional therapies 
is not well known.  
  Calcium, the most abundant mineral in the body, is responsible for numerous 
essential functions.  Calcium is absorbed primarily in the distal small intestine and is 
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utilized throughout the body for such functions as bone maintenance, to assist the 
transport of ions across cell membranes, to enhance some enzyme activities, for 
normal heart and skeletal muscle function, and for proper blood clotting (Mahan 
2004).   
 Human and mouse studies have provided evidence for a possible role for 
calcium in preventing and/or treating CRC.  Calcium stimulates expression of an 
membrane bound calcium-sensing receptor (CaR), and expression of this receptor 
appears to decrease with progression of human CRC (Chakrabarty, Wang et al. 
2005).  In another study it was shown that the role of extracellular calcium and its 
receptor in CRC is to promote E-cadherin expression and inhibit -catenin/TCF 
activation (Chakrabarty, Radjendirane et al. 2003).  One epidemiological study 
linked increased calcium and vitamin D intake with increased apoptosis in the rectal 
epithelium (Miller, Keku et al. 2005).   
 Developing human studies for determining the role for dietary supplements in 
preventing and treating CRC has proven to be difficult, mainly due to the large 
number of participants and extensive follow-up required.  In a review compiled by 
Weingarten, et al, 401 case-control studies, epidemiological studies and randomized 
controlled trials (RCTs) were reviewed revealing just two well-designed RCTs 
providing evidence for a potential preventative effect of calcium (Weingarten, 
Zalmanovici et al. 2005).  Doses of calcium supplementation in the two studies were 
2000mg/day and 1200mg/day (the recommended daily allowance) for 3 and 4 years, 
respectively.  Both studies revealed a moderate effect for calcium in preventing the 
development of colonic adenomas, but only the study using 1200mg calcium/day 
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reached statistical significance.  In a more recent study calcium supplementation of 
1200mg/day in patients previously diagnosed with colorectal adenomas had a 
protective effect even up to five years after the end of the study (Grau, Baron et al. 
2007).   
As a result of the inconsistency and difficulty with conducting human studies, 
cell lines and mouse models for CRC are being utilized to study the potential anti-
tumor mechanisms behind these supplements.  Several studies using mouse 
models for CRC have confirmed a role for calcium in increasing apoptosis in 
intestinal epithelial cells.  In one study using mice maintained on a Western-style diet 
that induced hyperproliferation and hyperplasia in the distal colon, supplementation 
with either tricalcium phosphate or calcium citrate reversed both hyperproliferation 
and hyperplasia (Richter, Newmark et al. 1995).  In another study B6 mice were 
maintained on either a control diet with 0.5% calcium or a diet supplemented with 
1.0% calcium, doubling the recommended intake of calcium and increasing 
apoptosis while having no effect on proliferation in the distal colon (Penman, Liang 
et al. 2000).  Finally, in a carcinogen-induced rat model for CRC, even low levels of 
calcium supplementation (40% increase above recommended dose) resulted in 
inhibition of colon carcinogenesis and altered distribution of tumors from the 
proximal to distal colon (Vinas-Salas, Biendicho-Palau et al. 1998).        
In addition to recognizing the role of diet in CRC, newly developed targeted 
therapies are being clinically tested and approved for use alone or in combination 
with other treatments for CRC.  In preclinical trials animal models are being used for 
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the study of the etiology of CRC and improving therapies; among those are the 
ApcMin/+ and azoxymethane (AOM) carcinogen-treated mouse models.   
The APC (adenomatous polyposis coli) gene encodes a tumor suppressor 
protein that is responsible for the degradation of CATNNB and prevention of WNT-
mediated signal transduction.  When APC is mutated, like the germ-line APC 
mutations responsible for familial adenomatous polyposis (FAP), CATNNB is not 
degraded, permitting it to function as a transcriptional co-activator with the TCF (T 
cell factor) family of transcription factors and leading to cellular transformation.  This 
results in hundreds to thousands of intestinal adenomas in humans.  When left 
untreated, these adenomas can lead to CRC.  APC is also somatically mutated in 
about 85% of sporadic or non-familial CRCs (Jen, Powell et al. 1994).  The ApcMin/+ 
mouse model is widely used to study colorectal tumorigenesis and the response of 
these tumors to potential therapies for CRC.  Although there are subtle differences 
between FAP patients and ApcMin/+ mice, such as the distribution of intestinal and 
colonic polyps, the ApcMin/+ model is nonetheless an excellent model to test CRC 
response to therapeutics because the identical pathway is perturbed in both humans 
and mice. 
Another model commonly used to study CRC promotion and treatment is the 
AOM model.  Since mice rarely develop spontaneous colon tumors, the colon-
specific carcinogen AOM can be used to induce CRC.  AOM is an alkylating agent 
that forms DNA adducts resulting in mutations primarily resulting in tumors in the 
colon, that are APC-mediated like in the ApcMin/+ model (Takahashi and 
Wakabayashi 2004). 
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An anti-cancer target commonly pursued with pharmacological agents is the 
epidermal growth factor receptor (EGFR).  Aberrant signaling of the EGFR pathway 
is a common occurrence in cancers, where it is deregulated in up to 50% of 
epithelial cancers (Harari, Allen et al. 2007).  Numerous agents that have been 
developed to target EGFR are currently being investigated in clinical trials or have 
been approved for clinical use.  These therapies include small molecule inhibitors 
that target the kinase domain and blocking antibodies against the ligand-binding 
domain.  
 It has been previously shown that ApcMin/+ tumors display increased EGFR 
activity, and that treatment with small molecule EGFR inhibitors results in a 
significant decrease in tumor incidence (Torrance, Jackson et al. 2000; Roberts, Min 
et al. 2002; Moran, Hunt et al. 2004).  In addition, though preclinical studies have yet 
to show efficacy of EGFR-inhibition in the AOM model, AOM-induced tumors show 
increased EGFR activity (Malecka-Panas, Fligiel et al. 1996).  Therefore it is 
reasonable to hypothesize that this model will also respond to EGFR-targeted 
therapies. 
Crosstalk between EGFR and other signaling pathways, including CaR, is 
being revealed.  Calcium binds the G-protein coupled receptor CaR, and GPCRs are 
known to transactivate receptor tyrosine kinases such as EGFR.  EGFR-inhibition 
using AG1478 has been shown to inhibit calcium-mediated proliferation of rat cancer 
and fibroblast cells (Tfelt-Hansen, Yano et al. 2005; Tomlins, Bolllinger et al. 2005).  
CaR possibly transactivates EGFR via regulation of proteolysis and shedding of 
EGFR ligands (Tomlins, Bolllinger et al. 2005).  Another model has been proposed 
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implicating calcium in mediating EGFR activation (Sato, Pallavi et al. 2006).  The 
intracellular calcium/calmodulin complex binds the juxtamembrane region of EGFR 
releasing the kinase domain from the membrane thereby facilitating activation of the 
receptor.  Conversely, depletion of calcium was recently shown to cause increased 
EGFR signaling via increased CDC42 activity which in turn led to increased E-
cadherin degradation in MCF-7 breast cancer cells (Shen, Hirsch et al. 2007).   
Since studies have implicated many dietary supplements as being anti-
tumorigenic, we hypothesize that complementing new conventional targeted 
therapies with these supplements may have an additive or even synergistic effects 
on reducing tumor growth. However, it is equally likely that supplements may 
interfere with the inhibitors.  Consequently, it is important to understand how dietary 
supplements interact with conventional treatments. 
 
Materials and Methods 
Experimental Design 
 Equal numbers of male and female A/J (A) mice were obtained from The 
Jackson Laboratory (Bar Harbor, ME) and maintained on mouse chow (LabDiet 
5058, Richmond, Indiana).  At four months of age mice were injected weekly with 
AOM (10 mg/kg body weight) for six weeks.  One week after the last AOM injection 
mice were randomly assigned to one of two diets, control (0.05% calcium) or calcium 
supplemented (5% calcium), with or without 144mg/kg chow of EGFR-inhibitor 
AG1478 (LC Labs, Woburn, MA) for 12 weeks.  At the end of treatment mice were 
euthanized by CO2 asphyxiation and colons were flushed with phosphate buffered 
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saline (PBS), splayed on bibulous paper, and scored for tumor number, size and 
location from the rectum.   
 ApcMin/+ on B6 males were mated to wild-type B6 females, and progeny 
containing the ApcMin/+ allele were weaned at 3 weeks of age and assigned to one of 
the same four calcium diets used for the AOM model.  After 9 weeks of treatment 
mice were euthanized by CO2 asphyxiation and the entire intestinal tract was flushed 
with PBS and splayed on bibulous paper.  The intestine was divided into four 
sections: small intestine (duodenum, jejunum, and ileum) and large intestine (colon) 
and scored for tumor number and size.   
 All mice were housed in an AAALAC approved-facility and provided chow and 
water ad libitum.  All experiments were approved by the Institutional Animal Care 
and Use Committee. 
 
Monitoring general health 
 Body weight was monitored biweekly for the AOM model and weekly for the 
Apc
Min/+ model.  Food weight was recorded at the beginning and end of treatment for 
Apc
Min/+ mice and biweekly for AOM mice to estimated consumption.  Blood glucose 
was measured using a FreeStyle Glucose Meter at the end of treatment.  Serum 
was collected for measurement of alanine aminotransferase (ALT) and calcium 
levels. 
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Phosphatase inhibitor treatment and protein extraction 
 Prior to euthanization mice were injected with 10μl/g body weight of 5mM 
phosphatase inhibitor sodium orthovanadate activated with 50mM hydrogen 
peroxide 15 minutes prior to use (Ruff, Chen et al. 1997).  Five minutes after 
injection, livers were dissected and snap frozen in liquid nitrogen.  For western blot 
analysis, total protein was extracted with lysis buffer containing 10mM Tris-HCl (pH 
8), 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM NaF, 1% NP-40, 10% glycerol, 
0.1% SDS, 0.5% sodium deoxycholate, 1mM PMSF, 10μg/ml leupeptin, 10μg/ml 
aprotinin, 1mM Na3VO4, and 1mM NaF.  A Bradford protein assay was used to 
determine protein concentration (Bio-Rad, Hercules, CA). 
 
Cell line treatments and MTT assay   
Human colorectal adenocarcinoma cells Caco-2 and carcinoma cells HCT116 
were obtained from the American Type Culture Collection (ATCC, Manassas, VA).  
Cell lines were maintained in RPMI-1640+L-glutamine medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum, 2.0mM L-glutamine, 
penicillin (10,000U/mL), and streptomycin (10,000U/mL).  Cells were grown at 37°C 
in 5%CO2. 
 Cells were treated with a dose range of 0.424mM (base concentration in 
media) to 5.5mM calcium chloride (Sigma, St.Louis, MO) dissolved in media 
immediately before use.  For EGFR-inhbitor treatment, AG1478 (LC Labs, Woburn, 
MA) was dissolved in DMSO and cells were treated with a dose range of 0 to 15μM 
with a final DMSO concentration of 0.1%.  
 70
For determination of cell viability cells were seeded on 48-well plates (4.0x104 
Caco-2 cells/well or 2.5x104 HCT116 cells/well) in triplicates 24hrs before treatment.  
Cells were treated daily and viability data was obtained at t = 72 hrs after plating for 
Caco-2 cells, and t = 96 hrs after plating for HCT-116 cells.                 
 Relative cell growth was assayed with an MTT Cell Growth Determination Kit 
(Sigma, St.Louis, MO) according to manufacturer’s instructions, and measured with 
a Beckman-Coulter DU 800 UV/Vis spectrophotometer. Relative cell viability was 
determined by normalizing to the control (0.1% DMSO treated) cells.  
 
Cell line protein extraction 
 For western blot analysis 5x105cells/60mm plate were seeded and 24hrs later 
treated as described above with increasing doses of CaCl2 (0.424 to 5.5mM) and 
with or without 4μM (Caco-2) or 8μM (HCT116) AG1478.  Following 24hrs of 
treatment protein was extracted with buffer containing 20mM HEPES (pH 7.4), 
150mM NaCl, 10% Glycerol, 1% Triton X-100, 1mM PMSF, 10μg/ml leupeptin, 
10μg/ml aprotinin, 1mM Na3VO4, and 1mM NaF.  A Bradford protein assay was used 
to determine protein concentration (Bio-Rad, Hercules, CA). 
 
Western blot analysis 
 For analysis, thirty μg of liver protein or fifteen μg of cell lysate was loaded 
onto 4-15% gradient Tris-HC gels (Bio-Rad, Hercules, CA).  After transfer to PVDF 
membranes for one hour, membranes were blocked for one hour in 
5%BSA/TBS(0.1% Tween) for rabbit anti-pEGFR, anti-pAKT, and anti-pMAPK44/42 
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(Cell Signaling, Danvers, MA) or 5%milk/TBST(0.1%) for sheep anti-EGFR 
(Millipore, Billerica, MA) and mouse anti-actin (Sigma, St.Louis, MO).  Membranes 
were incubated with primary antibody overnight at 4°C, pEGFR , pAKT, and 
pMAPK44/42 diluted 1:2,000 in 1%BSA/TBST, EGFR diluted 1:5,000 and -actin 
diluted 1:10,000 in 5%milk/TBST.  After washing, membranes were incubated in 
secondary antibodies for one hour at room temperature.  Secondary antibodies 
(Jackson ImmunoResearch, West Grove, PA) were diluted 1:20,000 in same 
solution as primary antibody.  SuperSignal West Dura Extended Duration ECL 
(Pierce, Rockford, IL) was used for visualization of proteins. Three replicates were 
performed per treatment and model (and gender for mouse models). 
  
ELISA for pEGFR 
 Cells were plated onto 60mm plates and treated with AG1478 and/or calcium 
chloride as described above.  Cells were treated for 2 hours, followed by addition of 
100ng/ml EGF (R&D Systems Cat #236-EG, Minneapolis, MN).  After 20 minute 
EGF treatment, protein was isolated as described above.  The STAR phospho-
EGFR (Tyr1173) ELISA Kit (Millipore Cat #17-461, Billerica, MA) was used 
according to manufacturer’s instructions.  Two replicates, 50μg each, of each 
sample was used. 
 
Statistical analysis 
 Tumor number and size data were analyzed using non-parametric Mann 
Whitney (Prism 4.0, GraphPad Software, Inc.). 
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 Linear mixed models were performed to assess whether calcium levels and 
inhibitor were associated with absorption levels.  Models were evaluated with cell 
lines treated as a random effect (Caco-2 and HCT116) and calcium levels (0.424, 
1.5, 2.5, 3.5, 4.5, 5.5mM) analyzed as both a linear effect (1 df) and without any 
constraints (5 df).  Tests for an interaction effect between calcium levels and inhibitor 
on absorbance levels were performed to assess whether the effects of calcium 
levels and inhibitor on absorbance levels were independent (additive).  Finally, 
stratified analyses were performed by cell type to assess whether evidence for any 
associations between calcium levels/inhibitor and absorbance levels was present in 
either cell types. 
Analysis of covariance (ANCOVA) models were performed to test whether 
model (AOM, ApcMin/+), sex, calcium intake and inhibitor were associated with 
glucose levels, serum calcium levels and ALT.  Tests of interactions were also 
performed. 
A non-parametric Mann Whitney test was performed on final body weight for 
mice in each treatment group (calcium and non-calcium), separated by sex (Prism). 
 
Results 
Calcium supplementation enhances AG1478 effect on tumor number reduction 
 Two models for CRC, ApcMin/+ and AOM, were assigned to either a Western-
style diet with low calcium (0.05%) or a calcium-supplemented diet (5%), each with 
or without EGFR-inhibitor AG1478 and treated for 9 and 12 weeks, respectively 
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(Figure 7).   At the end of treatment tumor number and size was assessed in the 
small intestine and colon of ApcMin/+ mice and colon of AOM-treated mice.   
 AG1478 did not significantly reduce tumor number in the ApcMin/+ model. 
However, supplementation with calcium in addition to AG1478 significantly reduced 
tumor number compared to AG1478 alone in colon (Figure 8a).  Each of the 
treatments, AG1478, calcium and AG1478/calcium, significantly reduced tumor size 
in the small intestine of ApcMin/+ model. 
 Contrary to the ApcMin/+ model, AG1478 significantly reduced tumor number in 
the AOM model, and supplementation with calcium further reduced tumor number, 
but the additive effect was observed only in female mice (Figure 8b).  None of the 
treatments impacted tumor size in the AOM model (data not shown).  Calcium alone 
did not reduce tumor number in either model. 
 Tumor distribution was determined by location of the tumors along small 
intestinal (duodenum, jejunum, or ileum) or large intestinal (colon) tract for ApcMin/+ 
mice and by distance from the rectal end of the colon (calculated as percent of total 
length of the colon within each mouse) in AOM-treated mice (Appendix).  No 
significant impact of treatment on distribution was observed. 
 Unlike the ApcMin/+ model, penetrance of AOM-induced tumors was variable.  
On the A background, penetrance was near 100%, and we did not observe any 
significant change as a result of treatment (Appendix Figure 16). 
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Calcium enhances AG1478-mediated decreased viability in human CRC cell lines 
 A dose dependent impact of calcium on AG1478-mediated reduction in cell 
growth, measured by an MTT assay, was observed in two human CRC cell lines, 
Caco-2 and HCT116.  Cells were treated with increasing doses of calcium chloride 
ranging from 0.424 (base concentration in media) to 5.5mM, with or without AG1478 
(4μM for Caco-2 and 8μM for HCT116).  AG1478 doses for each cell line were 
based on effective doses of less than 20% on cell viability (Fig. 9a), so that potential 
additive or synergistic interactions with calcium chloride may be observed.  When 
combined, AG1478 and calcium chloride had an additive effect on cell viability 
reduction (Figure 9c,d; p<0.0001), compared to calcium or AG1478 alone (Figure 
9a,b).   
 
Western blot analysis of calcium and AG1478 impact on EGFR signaling 
 Decreased EGFR activity, as measured by lower levels of phosphorylated 
EGFR (pEGFR) or downstream signaling molecules like phospho-AKT and 
phospho-44/42 MAPK (pERK1/2), should be indicative to target inhibition by 
AG1478.  In addition to total EGFR, phosphorylated proteins were analyzed by sex 
since sex-dependent effects were observed in overall tumor number and in response 
to AG1478/calcium in AOM-treated mice (Appendix). 
 EGFR activity was measured in livers extracted from phosphatase-inhibitor 
treated mice.  Although ApcMin/+ mice showed no response to AG1478 treatment 
(Figure 10a, left), AOM-treated mice exhibited decreased pEGFR in response to 
AG1478 and AG1478/calcium (Figure 10a, right) consistent with the observed 
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reduction in tumor number.  Calcium alone did not significantly reduce tumor number 
in either model, and this is reflected in EGFR signaling in ApcMin/+ mice of both sexes 
and AOM-treated females.  Additionally, while AG1478/calcium has an additive 
effect on tumor reduction in ApcMin/+ mice of both sexes and AOM-treated females, 
this is not reflected in EGFR signaling.  Calcium alone does induce downstream 
EGFR signaling in ApcMin/+ mice and this is inhibited with addition of AG1478. 
 The impact of calcium on AG1478-mediated EGFR inhibition was also 
examined in vitro.  Increasing levels of calcium along with AG1478 reduced EGFR 
downstream signaling in a dose-dependent manner (Figure 10b).  This inhibition was 
most evident in pAKT levels for Caco-2 and pERK levels for HCT116 cells.  pEGFR 
levels were too low for detection using western blot analysis, consequently cells 
were treated for 2 hours with AG1478 and/or calcium followed by EGF induction of 
EGFR.  ELISA was performed (Figure 10c) revealing that AG1478 reduced pEGFR 
and calcium supplementation alone may actually enhance pEGFR, especially in the 
Caco-2 cell line.  In both cell lines, AG1478 effectively reduced pEGFR regardless of 
calcium dose.  pEGFR levels in AG1478-treated cells were too low for detection of 
an additive effect between calcium and AG1478.  
 
Toxicity of in vivo calcium treatment  
 Several measurements were taken throughout treatment and at the end of 
treatment to monitor general health of the mice.  Weekly and biweekly body weight 
was measured for ApcMin/+ and AOM-treated mice, respectively (Figure 11a,b). 
Calcium treated mice, especially females, experienced weight loss despite the 
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treatment being advantageous with regards to tumor number.  Calcium treated 
Apc
Min/+ females had significantly lower body weight at the end of treatment 
(p=0.0011).  Additionally, AOM-treated females fed a diet supplemented with 
calcium in addition to AG1478 resulted in 26.7% death before the end of treatment 
compared to 0% with the AG1478 alone (Figure 11c).   
 Blood tests were performed in order to investigate the declining health of 
calcium treated mice despite the potential for it to enhance AG1478-mediated tumor 
reduction.  Typically calcium is tightly regulated in the body, maintaining a 
homeostatic level of calcium in the serum.  However, it appears that both AG1478 
(p=0.011) and calcium (p=0.014) are associated with increased serum calcium 
levels in each mouse model (Figure 12a).  In both models serum calcium levels in 
control mice were within the normal range, but AG1478 and calcium treatments 
increased serum calcium above the normal upper limit.  In addition, alanine 
aminotransferase (ALT) levels were measured as an indicator of liver toxicity, and 
AOM-treated mice given a diet supplemented with calcium had significantly higher 
ALT levels compared to the control (Figure 12b; p=0.0003).  Overall ALT levels were 
higher in females than males (p=0.025). 
 At the end of treatment, blood glucose levels were measured and a strong 
interaction between mouse model and inhibitor was observed (Figure 12c; 
p=0.0012).  AG1478 has an effect in both models but works in opposite directions 
(decreasing glucose in ApcMin/+ and increasing glucose in AOM-treated mice), which 
is reflective of the effect on tumor reduction.  When data from both models is 
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combined, a trend towards an association between calcium intake and glucose 
reduction is observed (p=0.062). 
 
Discussion 
 With diet at the forefront of many diseases, including cancer, and with dietary 
and herbal supplements gaining increasing popularity, preclinical studies designed 
to take into consideration as many human characteristics as possible is critical.  To 
date literature reporting the usefulness of dietary supplements in complementing or 
replacing conventional treatments for cancer has been inconsistent and incomplete.  
While many molecular targets have been identified for these dietary supplements, 
their efficacy in treating or preventing cancer is unclear, in large part due to the 
difficulty faced when studying supplements and diets in humans.  Perhaps more 
importantly, their impact on cancer therapies, and on general health at high doses, is 
not well understood. 
 The current study was designed to investigate the impact of dietary 
supplements, in particular calcium, on molecule-targeted therapies for CRC.  
Calcium alone has been intensely studied and is known to have many roles in cell 
physiology, as well as interactions with pathways involved in cancer.  It has been 
suggested that calcium possesses anti-tumor effects, but the mechanism is unclear.  
Some theories involving the role of calcium in colonic tumorigenesis include 
increasing apoptosis or inhibition of proliferation in the colon, and binding bile salts 
that result from diets high in fat and have been associated with colonic 
carcinogenesis (Holt 1999). 
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 In this study we observed an anti-tumor effect with calcium treatment in 
human CRC cell lines.  In vivo mouse models for CRC did not reveal a similar effect 
on tumor growth.  However, in both in vivo and in vitro models, an additive effect is 
observed when combining EGFR-targeted inhibitor AG1478 with calcium.  This is 
especially interesting in the ApcMin/+ model where mice are unresponsive to AG1478 
or calcium alone, but colonic tumors are reduced in the combinatorial treatment.  In 
the AOM model this additive effect is only observed in females.  In vitro the additive 
effect appears to be stronger in the Caco-2 cell line than HCT116 cells. 
 First, it appears that calcium may be more effective in the distal region of the 
intestinal tract since reduction in tumor number is only observed in the colons of 
Apc
Min/+ and AOM-treated mice on AG1478/calcium.  However, calcium alone does 
appear to reduce tumor size in the small intestine of ApcMin/+ mice.   
 Second, the stronger effect observed in Caco-2 cells may reflect the higher 
levels of CaR reported in more differentiated tumors, since Caco-2 cells were 
derived from a less progressed tumor than HCT116.   
 Finally, a sex-dependent effect on both EGFR signaling and tumor reduction 
was observed in the mouse models.  Among the pathways that crosstalk with 
calcium and its receptor CaR is EGFR, a pathway commonly deregulated in CRC.  
Calcium has been shown to influence EGFR signaling through G-protein coupled 
receptors and PKC.  Due to sex differences observed here, it is also possible that an 
interaction between CaR, EGFR and estrogen receptors (ER) is contributing to the 
variable sex results with regards to AOM tumor reduction and EGFR signaling 
revealed through western blot analysis. 
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 In addition to the benefits of calcium supplementation, potential negative 
effects on overall health must be considered.  Treatment with a high dose of calcium 
appeared to cause hypercalcemia, indicated by increased serum calcium and 
decreased body weight.  Liver toxicity also appeared to be higher according to ALT 
levels. 
 Further studies are necessary to unravel the mechanism through which 
calcium augments EGFR inhibitor-mediated tumor growth reduction.  It will also be 
essential to evaluate lower in vivo doses of calcium in order to determine if this 
additive effect is still observed once the toxic side effects of the combinatorial 
therapy are eliminated. 
 We conclude that the impact of dietary supplementation on conventional 
cancer therapies should be given consideration in future preclinical and clinical trials. 
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Figure 7.  Experimental design.  At weaning (ApcMin/+) or 1 week following the last 
carcinogen treatment (AOM) mice were randomly assigned to a Control (0.05% 
calcium) or Calcium (5% calcium) supplemented diet, with or without small-molecule 
EGFR inhibitor AG1478. 
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Figure 8.  Effect of Calcium on AG1478-mediated tumor number reduction in (a) 
Apc
Min/+ small intestine and colon and (b) AOM colon, and (c) tumor size in ApcMin/+ 
small intestine, expressed as a percent of Control treatment. [n  (a) 10 mice; (b) 18 
mice; (c) 692 tumors]  **p<0.0001 
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p=0.007 
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Figure 9.  Dose dependent effect on cell viability, measured using MTT assay, of 
human CRC cell lines Caco-2 and HCT116 exposed to increasing doses of (a) 
AG1478, (b) calcium chloride, (c) a constant AG1478 dose (4μM for Caco-2 and 
8μM for HCT116) with increasing doses of calcium chloride.  p<0.0001 
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Figure 10.  Western blot analysis of AG1478 activity.  (a) Mice maintained on a 
Control or Calcium supplemented diet, with or without AG1478, were injected with 
phosphatase inhibitor prior to euthanasia.  EGFR activation and downstream EGFR 
signaling were measured in liver protein lysates from APCMin/+ and AOM mice, 
separately for each strain and sex.  (b) Protein was extracted from human CRC cells 
lines after 4 hour treatment with or without 4μM (Caco-2) or 8μM AG1478 (HCT116) 
with 3.5mM (“+”) and 4.5mM (“++”) calcium chloride.  (c) pEGFR ELISA was 
performed using protein extracted from cells lines after 2 hour treatment with or 
without 4μM (Caco-2) or 8μM AG1478 (HCT116) with 3.5mM (“+”) and 4.5mM (“++”) 
calcium chloride followed by 20 minute treatment with EGF. 
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Figure 11.  General health of mice.  Comparison of body weight change for (a) 
Apc
Min/+ and (b) AOM mice maintained on a Control (solid lines) or Calcium (dashed 
lines) supplemented diets, with or without AG1478.  (c) Percent of mice (numbers in 
bars) that died (black) before end of treatment. 
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Figure 12.  Blood chemistry of ApcMin/+ and AOM mice maintained on a Control or 
Calcium supplemented diet, with or without AG1478.  Blood collected at the end of 
treatment was used for measurement of (a) serum calcium, (b) alanine 
aminotransferase (ALT), and (c) glucose levels.  The normal lower and upper levels 
are indicated for each test. 
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CHAPTER 4 
 
 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
 
Many new, molecule-targeted drugs have been developed for the treatment of 
cancer.  In vitro cell-based systems and in vivo animal models have been useful for 
identifying molecular targets for these new drugs.  Preclinical studies have 
successfully modeled not only the therapeutic effects of new drugs, but also 
potential side effects observed in human trials, including inflammatory dermatitis, a 
common side effect of EGFR-targeted therapy that correlates with drug 
effectiveness (Roberts, Arteaga et al. 2004).  While these model systems continue to 
provide valuable information for treatment of human cancers, clinical trials are 
frequently less successful than the preclinical results used to move new therapies 
into the clinic.  Preclinical studies designed to address the complexities of diet and 
genetic heterogeneity encountered in human trials should improve the power in 
predicting the effectiveness of new therapies. 
To better understand how different factors can impact preclinical studies, we 
investigated an EGFR-targeted treatment for colorectal cancer (CRC) using two 
model systems on different genetic backgrounds and diets.  The small molecule 
inhibitor of EGFR, AG1478, was tested in the ApcMin/+ and AOM mouse models of 
colorectal cancer.  The vast majority of published preclinical studies were conducted 
in mice maintained on a standard mouse chow.  Therefore, we used a standard 
mouse chow (STD) as well as a Western-style diet (WD) designed to resemble the 
current diet consumed by most potential patients in the United States.   
In both mouse models, AG1478 reduced tumor incidence. However the effect 
was dependent on the diet used.  Only ApcMin/+ mice maintained on the STD and 
only AOM mice maintained on the WD responded to AG1478 (Table 4a).  Differential 
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effects of AG1478 on tumor size were also observed (Table 4b).  While AG1478 did 
not reduce tumor number in ApcMin/+ mice maintained on the WD or AOM-treated 
mice maintained on the STD, it was effective in reducing tumor size when combined 
with these diets.   
Each model was used in combination with a genetic background highly 
susceptible to tumor induction for the particular model, B6 for ApcMin/+ and A for 
AOM.  We also investigated a common AB6F1 hybrid background for AG1478 
efficacy using both models. The hybrid genetic background was sensitive to 
AG1478-mediated tumor reduction when combined with either diet in the ApcMin/+ 
model but no AG1478-mediated tumor reduction was seen when combined with 
either diet with the AOM model (Table 4a).  The impact of AG1478 on tumor size in 
AB6F1 mice is consistent with its influence on tumor number, effective when 
combined with either diet in AB6F1-ApcMin/+ mice and not effective on either diet in 
AOM-treated AB6F1 mice (Table 4b). 
Similar to the variability observed in human trials of EGFR inhibitors, AG1478 
impacts tumor growth differently between genetic background and model. Genetic 
background alone does not appear to account for model differences since when both 
models are on the same AB6F1 background, opposing responses are still observed.  
Therefore, it is necessary to consider other physiological and molecular 
characteristics possibly contributing to these responses.   
There are several differences between the two mouse models that must be 
considered to understand the discrepancy in response to AG1478 (Table 5).  
Differences also include susceptibility to diet-induced obesity, timing and route of 
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initiation of cancer phenotype, distribution of tumors, and possibly microflora 
(Vaahtovuo, Toivanen et al. 2001).  However, differences between diet-induced 
obesity and microflora may be minimized when on the common AB6F1 background. 
Using a common background allowed us to focus on model differences.  
Since we still observe opposing responses to AG1478 between the two models, we 
must consider other model characteristics.  AG1478 is effective on both diets in 
Apc
Min/+ mice, but only in the small intestine, so one likely explanation is that 
AG1478 is not useful for inhibiting colonic tumors, whether the tumors are induced 
by the ApcMin mutation or the AOM carcinogen. 
Differences between the two inbred strains used in the study, B6 and A, 
include response to changes in diet such as fat levels.  B6 mice are susceptible to 
diet-induced obesity, whereas A mice are resistant (West, Boozer et al. 1992).  Two 
decades ago Surwit, et al. demonstrated that B6 are susceptible to Type 2 diabetes 
(T2D), a component of metabolic sydrome associated with obesity and characterized 
by insulin resistance and hyperglycemia (Surwit, Kuhn et al. 1988).  A more recent 
study, however, reveals the differential response of these two strains to a diet high in 
fat with regards to parameters of metabolic syndrome.  Although A mice are 
resistant to T2D, A males experience insulin resistance and glucose intolerance 
(Gallou-Kabani, Vige et al. 2007).   
In the current study, irrespective of diet or the presence of AG1478, AB6F1 
mice weighed more than either parental inbred strain.  The potential impact of weight 
gain and food consumption shifting the efficacy of AG1478 in the AOM model from 
favoring a combination with WD in A mice to being ineffective on both diets in AB6F1 
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mice is not clear, but body weight/percent body fat have known roles in drug 
absorption and clearance.  In addition, while we do observe the expected higher 
glucose levels in B6 mice compared to A, we do not observe diet-dependent 
changes in glucose.  Rather, AB6F1 mice for the ApcMin/+ model but not the AOM 
model, reveal an interaction between genetic background and model in response to 
EGFR-dependent glucose metabolism. 
The current study has also revealed sex-dependent influences on overall 
tumor number in addition to response to WD.  Overall tumor number is higher in 
females treated with AOM on both backgrounds and AB6F1-ApcMin/+ small intestines 
but lower in female B6-ApcMin/+ colons compared to males (Appendix).  Additionally, 
only AOM-treated A females are prone to WD-induced tumorigenesis.  For this 
reason, sex differences were taken into consideration when investigating the impact 
of diet on AG1478 with regards to EGFR signaling.   
EGFR activity was evaluated in livers extracted from phosphatase inhibitor- 
treated mice as a measurement of AG1478 efficacy.  Similar to the impact of 
AG1478 on tumor growth, EGFR signaling appears to be variably affected 
depending on sex, model, background and diet.  Typically EGFR-inhibition results in 
reduced activation of EGFR (i.e., lower pEGFR, pAKT, and pERK1/2).  In this study 
EGFR activity in the liver was not consistently indicative of tumor reduction (Table 
6).  Decreased pEGFR was observed in AOM-treated mice treated with 
WD/AG1478, reflective of the tumor number reduction observed in these mice.  
Similarly, no inhibition of EGFR activity was observed in the AOM-treated AB6F1 
mice. In contrast, an increase in EGFR activity was observed in males, again 
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reflecting the lack of tumor number reduction observed in these mice.  Decreased 
EGFR activity is observed only in ApcMin/+ mice maintained on STD, regardless of 
genetic background, and no decrease is observed in B6-ApcMin/+ females.  Tumor 
reduction is observed when AG1478 is combined in the STD, but why B6 females do 
not reflect this with regards to EGFR signaling and why WD/AG1478 does not show 
reduced EGFR activity in the AB6F1 mice even though tumor reduction is observed, 
is not clear.  It is also not clear why, though consistent with tumor data, AG1478 
does not appear to reduce EGFR activity in AOM-treated AB6F1 mice. 
Possible explanations for inconsistency between tumor reduction and failure 
to inhibit EGFR signaling in the liver include stabilization of EGFR signaling through 
crosstalk with other pathways, for example the estrogen receptor (ER) in females.  In 
AOM-treated males on the A background, we observe decreased EGFR activity 
when AG1478 is combined with STD, but no significant decrease in tumor reduction, 
indicating that perhaps these tumors are not EGFR-dependent.  In cases where 
neither AG1478-mediated EGFR signaling reduction nor tumor inhibition is observed 
it is likely that some dietary component is interfering with the inhibitor.  It is also 
possible that signaling in the liver, despite being the site of AG1478 metabolism, is 
not entirely indicative of signaling in the tumors. 
 In a previous study conducted in our lab, diet and strain were shown to 
interact in determining susceptibility to AOM (Bissahoyo, Pearsall et al. 2005).  Data 
from strains used in the current study, A and B6, as well as an additional DBA/2J 
(D2) strain and F1 and F2 generations between D2 and B6, reveal no significant 
gender or diet dependent response to AOM.  The only significant factor among this 
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set of data is the number of AOM injections (Figure 18a), increased number of 
injections corresponding to higher tumor number.  It can be noted, though, that in the 
B6 AOM-resistant strain, the few animals that did develop tumors were female.   
We have compared the main components of the diets used in the previous 
study to the diets used in the current study as well as the chow normally used to 
maintain mice in our facility in an effort to determine why the current study produced 
a strong sex effect (Appendix).  Some striking differences between the low (5010) 
and high fat (5015) diets used in the previous study compared to the STD and WD in 
this study are fat content, calcium and vitamin D levels.  Fat is nearly twice as high in 
the WD as that in the high fat 5015 diet.  Also, the source of fat is significantly 
different, with the WD being composed of animal products versus that of 5015 being 
of fish origin.  Also, calcium and vitamin D levels are much lower in the WD and 
even in the STD than either the 5010 or 5015, and calcium is much higher in the 
calcium supplemented diet than any of the other diets (the sex influences on this 
supplementation will be discussed below).   
In addition to base diet, dietary supplementation and its impact on AG1478 
therapy were also examined.  Calcium supplementation (5%) alone compared to a 
Western diet lacking adequate amounts of calcium (0.05%) does not reduce tumor 
number in either ApcMin/+ or AOM mice, but when combined with AG1478 an additive 
effect on tumor number reduction is observed.  Again, we observe a sex-dependent 
response in that for the AOM model, only female mice displayed a significant 
additive effect on tumor reduction with Calcium/AG1478 treatment.  Calcium 
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supplementation alone as well as in combination with AG1478 also reduced the size 
of small intestinal tumors in ApcMin/+ mice.   
 Again, EGFR activity was evaluated in livers extracted from phosphatase 
inhibitor-treated mice as a measurement of calcium effect on AG1478 activity (Table 
7).  Calcium treatment alone appears to induce EGFR signaling, increasing pAKT in 
males and females and pERK in females.  This induction is blocked when AG1478 is 
added.  As noted before, AG1478 alone inhibits EGFR signaling in AOM-treated 
mice, and this inhibition is also observed in males treated with calcium/AG1478 but 
not in females.  The additive effect of calcium on AG1478 in reducing tumor number 
is not reflected in inhibition of EGFR signaling represented by pEGFR, pAKT and 
pERK levels.   
Calcium appears to interact with EGFR signaling, since calcium alone does 
not reduce tumor number.  We can additionally conclude that calcium, while 
appearing to induce EGFR signaling, does not interfere with AG1478 efficacy, with 
regards to effect on either tumor growth or EGFR signaling. 
 While calcium supplementation appears to be beneficial with regards to 
inhibiting intestinal tumor growth, it also seems that this treatment could be 
detrimental to general health.  Monitoring body weight and appearance throughout 
treatment revealed that calcium treated mice, especially females, declined more 
rapidly than those subjected to other treatments, despite these mice having fewer 
tumors.  
Serum calcium levels are normally tightly regulated, however, mice 
supplemented with calcium had significantly higher serum calcium levels.  
 103
Additionally, AOM mice treated with the calcium/AG1478 combination had 
significantly higher alanine aminotransferase (ALT) levels, indicative of liver toxicity.  
Calcium levels in the supplemented diets were ten times the recommended dose, 
and one-hundred times that found in the control Western-style diet.  
 It is not known how much the U.S. human population may exceed the 
recommended upper limit of calcium intake (2500mg/day), but calcium toxicity in 
humans is rare.  In general, calcium intake in humans in significantly less than the 
recommended 1200-1300mg/day (Straub 2007), and it has been recommended that 
supplements of no more than 500mg of elemental calcium be consumed at one time.  
While human CRC studies typically prescribe up to 1200-2000mg/day of elemental 
calcium (Weingarten, Zalmanovici et al. 2005; Grau, Baron et al. 2007), reporting 
mild side effects such as urinary stones and gastrointestinal distress, it is known that 
calcium does interact with some drugs and the potential to interact with cancer 
therapies resulting in more severe side effects should be considered.     
 Impact of calcium on AG1478-mediated EGFR inhibition was also examined 
in vitro, allowing us to examine calcium dose response.  In two human CRC cell 
lines, differing primarily in stage of cancer progression they were derived from, 
combining various doses of calcium with a constant dose of AG1478 resulted in 
additive reduction of cell viability compared to AG1478 or calcium treatment alone.  
Observations of cell growth and structure indicate that the doses reported here are 
not toxic. Further studies in mice with safer levels of calcium will be necessary in 
order to determine if there is still an additive effect with EGFR-targeted therapy in 
vivo. 
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While we did predict that diet and dietary supplementation would impact 
therapeutics such as EGFR-targeted small molecule inhibitors used in treating CRC, 
other factors surfaced that must be considered as well.  Among those factors are 
choice of model system, genetic background, and gender.   
The interaction between sex, diet and CRC incidence was addressed in a 
recent review of human clinical trials (Jacobs, Thompson et al. 2007), recognizing 
that it is difficult to separate sex differences in these published studies but that there 
does seem to be some trend of sex influence with regards to particular dietary 
factors.  First, tumor distribution seems to be influenced by sex, with females being 
more vulnerable to proximal colon tumors and males being more likely to develop 
tumors of the distal colon.  However, interaction between sex and diet is less clear, 
as extrapolating sex differences in most reports is difficult.  The strongest link 
between diet, sex and CRC appears to be with regards to obesity, with the 
relationship between males, obesity and CRC being stronger than that for females.  
Other dietary influences, such as energy intake, red meat/fat consumption, vitamin D 
levels and calcium appear to equally affect males and females with regards to CRC 
susceptibility.  Sex-influenced responses to EGFR-targeted therapies also have yet 
to be reported.   
The sex-dependent response to AG1478 observed in the current study could 
be a result of the interaction between the estrogen receptor (ER) and EGFR.  In 
some cells estrogen has been shown to transactivate EGFR signaling through a G-
protein coupled receptor (Filardo 2002).  It has also been demonstrated that 
estrogen receptor  (ER) is expressed in the colon and is lower in cancer than 
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normal cells (Foley, Jazaeri et al. 2000).  Also, treatment of ApcMin/+ ovariectomized 
female mice with estrogen (17-estradiol) increases ER in the intestine and is 
associated with protection against tumors induced by ovariectomy (Weyant, 
Carothers et al. 2001).  Estrogen may play a role in CRC in addition to gynecologic 
cancers and ER may have a protective effect in the colon (Bardin, Boulle et al. 
2004).   
Another study highlighting a possible interaction between calcium, sex and 
CRC suggests that a low calcium diet (0.04%) induces COX2 expression, a protein 
associated with tumorigenesis, only in females, compared to a diet consisting of 
normal calcium levels (0.5%) (Bises, Bajna et al. 2007).  It is possible that varying 
calcium levels contribute to the sex influences observed in the current study.  A sex 
effect was not observed in the original AOM study, utilizing low versus moderate fat 
diets with normal calcium levels, but was observed in the current study utilizing a 
Western-style diet low in calcium versus a standard diet with normal calcium or a 
diet high in calcium.  It is possible that crosstalk between the calcium receptor 
(CaR), ER, and EGFR is contributing to the varying response.  Future studies should 
consider potential sex influences when designing and analyzing these studies. 
Along with sex and genetic background, it is likely that each model possesses 
different microflora (Vaahtovuo, Toivanen et al. 2001), and these differences may 
contribute to obesity susceptibility (Turnbaugh, Ley et al. 2006).  Microflora has a 
significant role in the metabolism of dietary agents, contributing to obesity as well as 
potentially other diet-related diseases (Cani and Delzenne 2007).  In one study, 
Apc
Min/+ mice that responded favorably to caloric-restriction or a diet containing high-
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olive oil, fruits and vegetables were also determined to have different microflora 
compared to a control diet (Mai, Colbert et al. 2007).   
The current study contributes new ideas for pre-clinical studies, designed to 
better predict cancer therapy outcomes in human clinical trials by modeling both the 
genetic heterogeneity of patient populations and the diets they consume.  While the 
data presented here provides evidence for the importance of gene-environment-
therapy interactions in developing and testing cancer therapeutics, future 
experiments will be needed to identify the underlying mechanisms and resolution of 
the conflicting results, as well as what can be expected in humans. 
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Table 4.  Summary of effect of Standard (STD) and Western-style (WD) base diets 
on AG1478-mediated tumor number (a) and size (b) ApcMinand AOM mice.  
 
  a)  Tumor number 
   
 
 
 
b)  Tumor size 
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Table 5.  Differences between mouse models/inbred strains used in this study. 
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Table 6.  Summary of impact of AG1478 on EGFR signaling in ApcMin/+ (B6 or  
AB6F1) and AOM (A or AB6F1) mice maintained on STD or WD.   
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Table 7. Summary of impact of AG1478, Calcium and Calcium/AG1478 on EGFR  
signaling in ApcMin/+ and AOM mice. 
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Table 8. Raw data for average tumor number (a) and tumor size (b).  
 
a) Tumor number 
 
b) Tumor size 
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Table 9.  Raw data for average tumor number of (a) females and (b) males. 
 
a) Female tumor number 
 
b) Male tumor number 
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Table 10.  Raw data for average tumor size for (a) females and (b) males. 
 
 a) Female tumor size 
 
 
 b) Male tumor size 
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Table 11.  Raw data for average tumor number (a) and tumor size (b). 
 
 a) Tumor number 
 
 
b) Tumor size 
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Table 12.  Raw data for average tumor number for (a) females and (b) males. 
 
 a) Female tumor number 
 
b) Male tumor number 
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Table 13.  Raw data for average tumor size for (a) females (b) males. 
 
a) Female tumor size 
 
b) Male tumor size 
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Figure 13.  Distribution of tumors along small intestine and colon in ApcMin/+ (a) and 
along colon in AOM (b) mice.  Distribution is indicated by location in small intestine 
(duodenum, jejunum or ileum) or colon in ApcMin/+ mice and as percent distance from 
distal end of colon in AOM mice.
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Figure 14.  Distribution of tumors along small intestine and colon in ApcMin/+ (a) and 
along colon in AOM (b) mice.  Distribution is indicated by location in small intesine 
(Duodenum, Jejunum or Ileum) or Colon in ApcMin/+ mice and as percent distance 
from distal end of colon in AOM mice. 
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Figure 15.  Penetrance of AOM-induced colon tumorigenesis for mice maintained on 
STD or WD, with or without AG1478. 
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Figure 16.  Penetrance of AOM-induced colon tumorigenesis for mice maintained on 
a Control or Calcium diet, with or without AG1478. 
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Figure 17.  Insulin to glucose ratio for the AB6F1 strain of ApcMin/+ and AOM mice 
maintained on STD or WD, with or without AG1478.  [n = 4 mice per treatment per 
model]
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Figure 18.  Previous AOM data demonstrating differential impact on tumor number 
is gender and diet dependent.  (a) A/J mice maintained on low fat diet receiving 4 
versus 8 weekly AOM injections.  (b) inbred and (c) F1 and F2 generation strains 
receiving 4 weekly AOM injections while maintained on low or high fat diets.    **p  
0.005 
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Table 14.  Comparison of typical mouse chow (5058), low and high fat diets 
used in previous AOM study (5010 & 5015), and diets used in current study 
(STD, WD, and Calcium Supplemented). 
 
 
 
 
